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ABSTRACT
Estrogen plays multiple roles in health and disease, exerting its effects through the
classical estrogen receptors (ERα and ERβ) and the G protein-coupled estrogen
receptor (GPER). Current ER-targeting ligands, including the therapeutic ERα
antagonist tamoxifen, have been shown to cross-activate GPER. This
cross-activation is hypothesized to contribute to clinically observed endocrine
resistance in breast cancer, highlighting the potential benefit of truly ER-selective
antagonists. We report the identification of a novel class of ER-selective ligands
that lack cross-reactivity towards GPER, identifying a truly ER-selective agonist
(AB-1) and antagonist (AB-82P). Importantly, AB-82P degrades a clinically
relevant ERα mutant and exhibits inhibitory effects in cellular models of endocrine
resistance. This novel class of ER-selective ligands can aid in improving our
understanding of the individual estrogen receptors in estrogen biology and more
importantly, provide a structural basis for the development of new, truly
ER-selective antagonists for the treatment of ERα-positive breast cancers.
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CHAPTER 1
Introduction

1.1 Estrogen synthesis
Estrogen,

often

called

the

female

sex

hormone,

is

a

small

membrane-permeable molecule that plays a role in various systems in the female
body. It is present in three forms within the body: estrone (E1), estradiol (E2) and
estriol (E3) [1] (Fig. 1.1a). Estradiol, specifically 17β-estradiol, is the most
prevalent and potent form of estrogen in the body. Therefore, for the remainder of
this dissertation, when referring to estrogen, estradiol (E2, 17β-estradiol) will be
implied.
Estrogen, originally identified by Allen and Doisy, is mainly synthesized in
the ovaries of pre-menopausal women [2]. Stimulation of the ovaries by
follicle-stimulating hormone, produced by the pituitary gland (as a result of its
stimulation by gonadotropin-releasing hormone), results in the secretion of
testosterone by the ovaries. Testosterone is subsequently converted (in the
ovaries) to estrogen by the enzyme known as cytochrome P450 aromatase
(encoded by the CYP19A1 gene) [3]. This conversion step by aromatase is a
therapeutic target in breast cancer therapy and will be discussed later in this
chapter. In post-menopausal women, the ovaries stop producing estrogen,
resulting in a significant decrease in circulating estrogen levels. Although estrogen
production strongly decreases in the post-menopausal setting, women do continue
to produce lower levels of estrogen, mainly in skin and adipose tissue. This occurs
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through local conversion of testosterone and androstenedione to estrogen by the
aromatase enzyme (androstenedione is converted to E1 and subsequently to E2).
Contrary to the term “female sex hormone”, men also produce estrogen, but at a
much lower level than women (circulating estrogen levels in men are comparable
to that of post-menopausal women). In men, estrogen is produced in tissues such
as the testes (e.g. by Leydig cells) and brain [4].
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Figure 1.1. Structure of estrogens and the human classical estrogen receptors. (a) Structures of
estrone (E1), estradiol (E2, specifically 17β-estradiol) and estriol (E3). (b) Domain structures of
human ERα and human ERβ and the locations of important regions of the receptor. Sequence
homology (in percentages) of the various ERβ domains versus the corresponding domains in ERα
are shown. AF-1: activating function-1, AF-2: activating function-2, DBD: DNA-binding domain,
LBD: Ligand-binding domain.
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1.2 Physiological roles of estrogen
Estrogen (mainly E2) plays an important role in many physiological
processes [5], but its most well characterized role is that in female reproductive
organs. In the breast, estrogen is essential for the elongation of epithelial ducts
during puberty. This is exemplified by the observation that female ERα knockout
mice develop abnormal mammary glands in which no ductal elongation is
observed [6]. These mice have a mammary gland phenotype similar to that of a
neonatal mouse.
Estrogen is also important in the female reproductive tract. In ERα knockout
mice, the reproductive tract develops normally, however these mice are infertile.
This is in part due to the impaired role of estrogen in the ovaries of ERα knockout
mice. Estrogen plays a role in folliculogenesis and ovulation and ERα has been
shown to be the main ER involved in this role [6, 7]. ERβ knockout mice only have
partially disrupted folliculogenesis and are subfertile.
Contributing to the infertile phenotype of ERα knockout mice is the role of
estrogen in the maturation of the uterus. In ERα knockout mice, the uterus displays
a hypoplastic morphology (being small and shriveled) compared to the uterus in
wildtype female mice and is unresponsive to estrogen stimulation [6]. The uterus
is normally highly sensitive to estrogen and undergoes several changes when
stimulated with estrogen, a classical one being its increased absorption and
retention of water in a process termed imbibition [8]. Furthermore, uterine epithelial
cells also undergo increased cellular proliferation in response to estrogen. The
high sensitivity of the uterus to estrogen and its resulting water imbibition is
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exploited by researchers to test the estrogenicity of compounds (drugs) in vivo [9].
Aside from its role in female reproductive organs, estrogen also plays a role
in many other systems, including the cardiovascular, nervous and immune
systems and in the bone and metabolism [10]. For example, in the cardiovascular
system estrogen plays several roles including a protective role against arterial
hypertension, as is observed with the increase in arterial hypertension (and cardiac
disease) in post-menopausal women when the ovaries cease to produce estrogen
[11]. In the bone, estrogen plays a role in overall bone health and trabecular bone
growth. This is exemplified by the increased risk of developing osteoporosis in
post-menopausal women [10].
Overall, estrogen plays a role in many physiological processes in both
sexes and exerts its effect through three known estrogen receptors ERα, ERβ and
the G protein-coupled estrogen receptor (GPER). The receptors are discussed in
the following sections and readers are referred to the following comprehensive
references on the wide range of other physiological roles of estrogen in both men
and women [4, 5, 10].

1.3 Classical estrogen receptors alpha and beta (ERα and ERβ)
In the late 1950s, Jensen and Jacobson observed that the rat uterus and
vagina retained [3H]estradiol, whereas other tissues such as the liver and muscle
did not [12]. These observations (and others) led to the idea of the existence of a
receptor to estrogen. Later work led to the identification and characterization of an
estrogen receptor, which was eventually cloned in 1986 [13-15]. This receptor (the
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first hormone receptor to ever be identified), originally called the estrogen receptor,
was later termed estrogen receptor alpha (ERα), following the identification of a
second estrogen receptor in 1996, termed estrogen receptor beta (ERβ) [16].

1.3.1 Structure
ERα and ERβ, termed the classical estrogen receptors, are ligand
(hormone)-activated transcription factors. They belong to the nuclear hormone
(steroid) receptor superfamily (which includes e.g. the progesterone receptor and
the glucocorticoid receptor) and consist of two main domains: a DNA-binding
domain (DBD) and a ligand-binding domain (LBD) (Fig. 1.1b) [17-19]. The LBD is
a α-helix bundle, consisting of 12 α-helices; the ligand-binding pocket sitting
between helix 3 and 11 [20, 21]. A critical component of the ER-LBD is the
C-terminal helix, helix 12, which plays an important role in the activation of the
receptor (discussed below). ERα and ERβ share high homology between their
DBDs, but not between their LBDs, showing only ~60% homology in the latter [22,
23]. However, the binding cavity of their LBD are highly conserved and differ by
two residues [22]. The receptors also contain two functional sites that are involved
in transcriptional activity: the constitutively active activation function-1 (AF-1) site
and the ligand-dependent activation function-2 (AF-2) site. The latter is localized
in the LBD of the receptor and is responsible for ligand-induced transcriptional
activity of the receptors. The DBD and the LBD are linked together via a flexible
hinge domain which is thought to be important for their function [24]. Wildtype ERα,
a 66 kDa protein, has several splice variants: a 46 kDA variant (ER-46) [25] and
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the even shorter 36 kDa variant, ER-36 [26]. These splice variants lack the AF-1
region of the wildtype receptor and have been shown to act as inhibitors of ERα
signaling and capable of activating rapid signaling pathways [27]. Several isoforms
of ERβ have also been identified, but their roles are not well known [28].

1.3.2 Cellular localization
Classically, transcription factors are located in the nucleus where they exert
their genomic activity, however there are receptors, like inactive androgen
receptors, that are predominantly cytoplasmic, but translocate to the nucleus upon
activation [29, 30]. In the case of estrogen receptors, the majority (~95%) of the
inactive receptor is localized to the nucleus [31, 32]. However, a fraction of the
receptors are found in the cytosol. Interestingly, a fraction of the cytosolic splice
variants of ER have been found to localize to the plasma membrane, in particular
to caveolae. There, these splice variants have been implicated, at least in part, in
E2-induced rapid non-genomic signaling pathways like PI3K and eNOS synthesis
[33, 34].

1.3.3 Function
In their inactive, non-ligand-bound state, ERs are bound to chaperone
proteins like Hsp90 and p23 in the cell [32, 35]. Following binding to estrogen (E2
binding affinity for ERα and ERβ is 0.05-0.4 nM and 0.09-0.4 nM, respectively [23]),
the receptors undergo a conformational change that promotes the release of the
bound chaperone proteins and induces receptor dimerization (homodimers and
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heterodimers). Activated ER dimers subsequently bind to the promoters of target
genes in the nucleus at specific sites on the DNA, termed estrogen response
elements

(EREs)

[28].

EREs

have

the

general

consensus

sequence

5’-GGTCAnnnTGACC-3’ however, most ER binding sites do not have this exact
ERE sequence, varying by one or two nucleotides [36]. Known ERα target genes
that have an (imperfect) ERE sequence in their promoter include trefoil factor 1
(TFF1, also known as pS2) [37], progesterone receptor [38] and prolactin [39].
DNA-bound ERs subsequently induce or inhibit target gene transcription
through the recruitment of coactivators or corepressors, respectively, and initiate
proliferative and pro-survival signaling in the cell [18, 40, 41]. These coregulatory
proteins bind to AF-1 and/or AF-2 sites on ERs. In an inactive (unliganded)
receptor state, the AF-1 and AF-2 sites on ERs are hidden. Only following
activation of the ERs, do these sites become exposed and accessible for
coregulatory proteins to bind to them via a general LxxLL motif in the coregulatory
proteins [42]. The AF-1 region, which functions independently of ligand binding,
becomes exposed following activation of ERs by phosphorylation of residues near
the AF-1 region. Estrogen has been shown to induce phosphorylation of serines
104 and 106 in the AF-1 domain by cyclin A2-CDK2 [43]. Furthermore,
mitogen-activated protein kinase (MAPK) can phosphorylate ER at serine 118 in
response to growth factor signaling [44, 45]. Unlike the AF-1 region, the activity of
the AF-2 region is ligand-dependent. The AF-2 region is located in the ER-LBD
and its accessibility is governed by the location of a structurally important helix,
termed helix 12, in the LBD [46]. In an unliganded (or antagonist-bound), inactive
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state, helix 12 occupies the AF-2 site, through interaction with its own LxxML
sequence, thereby preventing the binding of coregulatory proteins [20]. In the
active, estrogen-bound (or agonist-bound) state, helix 12 moves down to lock
estrogen in place in the ligand-binding pocket. This conformational change
exposes the AF-2 site on the receptor, allowing coregulatory proteins to bind [47].
Thus, whereas AF-2 exposure is dependent on ligand binding, AF-1 can become
exposed in a ligand-independent manner; both resulting in transcriptional activity
of the receptor. While each activation function site can recruit its own distinct set
of coregulatory proteins, several coregulatory proteins can bind to both AF-1 and
AF-2 sites (e.g. SRC-1) [18]. Importantly, AF-1 and AF-2 work synergistically with
each other and full transcriptional activation of the receptor generally requires that
coactivators be recruited to both sites [48]. The recruitment of coregulatory
proteins to DNA-bound ERs is a complex phenomenon and leads to the
recruitment of basal transcription factors that alter chromatin structures and
eventually lead to the recruitment of RNA Polymerase II, ultimately leading to
proliferative, survival and migratory cellular responses [49, 50].
Activated ERs bind to DNA at EREs and regulate target gene transcription,
however ERs can also regulate transcriptional activity in other ways [51].
Ligand-bound ERs can modulate gene transcription of genes that do not contain
an ERE in their promoter region by indirectly binding to these promoters via other
DNA-bound transcription factors like activator protein-1 (AP-1) and specificity
protein 1 (Sp-1); serving as a docking site for additional regulatory proteins [17,
52].
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ERα and ERβ are often said to have opposing effects. In cells expressing
both receptor subtypes, ERβ is thought to inhibit ERα-mediated signaling. For
example, Matthews et al. showed that ERβ expression reduced ERα-mediated
transcription of the progesterone receptor (PR) [53]. Moreover, ERβ expression
could reduce ERα protein levels. Similarly, Liu et al. showed that ERβ inhibits
ERα-induced transcription of cyclin D1 [54]. The exact mechanism behind the
inhibitory effects of ERβ on ERα-mediated signaling is currently not understood,
but is thought to involve an ERβ-induced change in the recruitment of coregulatory
proteins by ERα [28, 53].
The complexity of ER signaling is further exemplified by the differential
responses that binding of different ligands (agonists or antagonists) elicits [55].
Different ligands induce different conformations of the ER LBD, which in turn recruit
different coregulatory proteins. Furthermore, differences in expression levels of
co-activators and co-regulators also influence the transcriptional activity of ERs
[40, 56]. One example of this being 4-hydroxytamoxifen (the active metabolite of
tamoxifen). 4-hydroxytamoxifen, an ER antagonist in the breast, acts as an ER
agonist in the endometrium. This is believed to be due to lower co-activator
expression levels in the breast versus that in the endometrium [40].
Aside from transcriptional signaling, ERs can also induce rapid,
non-genomic cellular responses, such as cyclic AMP (cAMP) production, calcium
mobilization and protein kinase activation (e.g. ERK), which result in the activation
of other pathways that can modulate gene transcription in an ER-independent
manner [23, 57]. These rapid signals are believed to, at least in part, originate from
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membrane-bound ERs (mentioned earlier, in the case of ER isoforms) [58].
ER-mediated activation of rapid signaling has been reported to occur through
binding of ERs to e.g. Src and PI3K, leading to downstream signaling [34].

1.3.4 ER degradation: means to limit ER signaling
Transcriptional activity of hormone receptors is dependent on the
intracellular protein levels of the receptor. These levels change with varying cellular
states [59]. In the case of the estrogen receptor, the major regulator of ER protein
levels is the presence of estrogen itself (a phenomenon shared with other hormone
receptors). Estrogen is able to induce ER degradation in an auto-regulatory
feedback loop, leading to a decrease in both ER protein and mRNA levels.
E2-induced ER degradation is part of how the cell regulates ER function, following
activation

of

the

receptor.

ubiquitin/proteasome-dependent

This
pathway

degradation
[60].

occurs

Ligand-bound

through
ERs

a
are

polyubiquitinated on residues in their C-terminus tail, in a process involving the E1,
E2 and E3 ubiquitin/ligase family and others [60, 61]. Lysine residues in the hinge
region of ERα (K302 and K303) have also been shown to be ubiquitinated [62].
The polyubiquitinated ER is then trafficked to the 26S proteasome complex for
degradation, completing the process of ER-signaling termination. Although ER
activity and degradation are linked, and coactivator binding is important, activation
of ER is not required for its degradation [61, 63]. One example being
ligand-induced ER degradation following binding of the ER antagonist ICI182,780
(discussed later) [64].

11

1.3.5 Ligand specificity between classical estrogen receptors
Due to the highly conserved binding pocket between ERα and ERβ,
subtype-selective ligands have been difficult to develop [22]. Both receptors bind
estrogen (E2, 17β-estradiol) with similar affinities (ERα: 0.05-0.4 nM, ERβ:
0.09-0.4 nM) [23]. Furthermore, both receptors can bind other natural and synthetic
environmental estrogens that mimic physiological estrogens (estrone, estradiol
and estriol). These environmental estrogens consist of e.g. phytoestrogens (such
as genistein) and xenoestrogens (such as bisphenol A) [23].
However, to date, no truly ERα-subtype nor truly ERβ-subtype selective
ligands exists. There do exist ligands that are biased towards one receptor over
the other. For example, 4,4’,4’-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT)
is an ERα agonist that shows ~400-fold binding preference for ERα over ERβ [65].
Inversely, DPN (2,3-bis(4-hydroxyphenyl)propionitrile) acts as an agonist of the
classical ERs, but has a ~70-fold higher affinity for ERβ over ERα (Fig. 1.2) [66].
A list of other partially subtype-selective ligands can be found here [22].

1.3.6 Tissue distribution
ERα and ERβ are expressed in multiple tissues. In some, both receptor subtypes
are expressed at similar levels, whereas in others one subtype is mainly expressed
over the other. In tissues where both subtypes are expressed, the individual
subtypes are generally expressed in different cell types within that tissue. ERα is
expressed e.g. in breast (luminal epithelial cells), bone, ovary (theca cells), uterus,
prostate (Leydig cells) and liver tissue. ERβ is expressed e.g. in breast (stromal
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and myoepithelial cells), ovary (granulosa cells), colon and lung tissue. Both
receptor subtypes are also expressed in various parts of the brain [1, 17, 67].
OH

N
N
HO

OH

PPT
OH

C
HO
N

DPN

Figure 1.2. Structures of ER subtype-biased compounds.

1.4 G protein-coupled estrogen receptor (GPER)
In the late 1990’s/early 2000’s it was already known that estrogen could
induce rapid, non-genomic signals (on the scale of seconds to minutes). However,
it was debated whether this E2-induced rapid signaling was mediated solely by
ERα and ERβ (previously discussed) or whether an unknown receptor was the key
mediator [68]. In the late 1990’s several laboratories identified an orphan G
protein-coupled receptor (GPCR), later be termed GPR30, that had no known
ligand [23, 69, 70]. Estrogen was later identified as the natural ligand of GPR30
(E2 Kd ~3 nM [71], IC50 ~7 nM [72]), leading to the renaming of the receptor to G
protein-coupled estrogen receptor (GPER) [71-75].
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1.4.1 Structure
GPCRs are the largest class of signaling receptors in eukaryotes. They
consist of 7-transmembrane spanning α-helices and are mainly localized to the
plasma membrane, but GPCRs are also present in other membranes inside the
cell [76]. GPCRs are organized in the membrane in such that their N-terminus is
extracellular while their C-terminus protrudes into the cytosol. The C-terminus of
GPCRs plays an important part in translating extracellular signals into the cell.
Moreover, it is an important region involved in terminating GPCR signaling.

1.4.2 Function and localization
Upon binding to a ligand, GPCRs undergo a conformational change that
allows them to bind intracellular heterotrimeric G proteins. This binding leads to
activation of the G proteins (through their binding of GTP) and subsequent
downstream activation of second messenger proteins (e.g. synthesis of cAMP and
activation of protein kinase A (PKA) and ion channels) [77, 78]. GPCR signaling is
terminated in a process involving intracellular phosphorylation of the GPCR by G
protein-coupled receptor kinases. These phosphorylated sites act as docking sites
for arrestins, which subsequently lead to the internalization, recycling and/or
degradation of the GPCR and eventual desensitization of the receptor [78, 79].
Although GPCRs are mainly located on the plasma membrane, they can also be
found in intracellular membranes. In the case of GPER, it has been shown to
mainly localize to the endoplasmic reticulum [72]. However, GPER has also been
detected, at lower levels, in other cellular locations, including the plasma
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membrane and the nucleus [80, 81]. Since its ligand (estrogen) is readily
membrane-permeable, GPER is not required to be at the plasma membrane to
engage with it.
Activation of GPER leads to the activation of an array of downstream rapid
signals, including the activation of ERK1/2, PI3K, cAMP synthesis and Ca 2+
mobilization (Fig. 1.3) [72, 75, 82]. Filardo et al. showed that E2-induced activation
of ERK1/2 occurred through the GPER-mediated transactivation of the epidermal
growth factor receptor (EGFR) by heparin-bound EGF (HB-EGF) [75]. Further
elucidation revealed that activation of GPER leads to the activation of Src and
matrix metalloproteases, which subsequently cleave HB-EGF and induce the
activation of EGFR and the resulting downstream ERK1/2 and PI3K pathways [82].
Aside from inducing rapid non-genomic signaling, GPER (following
E2-activation) also induces genomic signaling, however not to the same extent as
ERα and ERβ. Genes that are regulated by GPER include c-fos, which was shown
to be upregulated in an endometrial cancer cell line following stimulation with E2
[83]. Transcriptional regulation by GPER could occur via the cAMP/CREB
signaling axis (cAMP is a product of GPER activation), which is known to induce
transcription of c-fos [84, 85]. GPER has been reported to be present in the nucleus
of cancer-associated fibroblasts [81, 86, 87], where it is hypothesized to act as a
transcription factor, possibly in a complex with EGFR [87]. However, the
mechanism through which GPER could potentially act as a transcription factor is
not clearly understood. A comprehensive list of GPER-regulated genes can be
found here [82].
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Thus, E2-induced activation of GPER results in the activation of a range of
rapid, non-genomic pathways, that lead to proliferative, migratory and pro-survival
cellular responses. Furthermore, GPER can regulate some genes, however it is
mainly associated with E2-induced rapid, non-genomic signaling.

Figure 1.3. Pathways activated by GPER and the classical ERs. Estrogen, environmental estrogens
and tamoxifen are hydrophobic compounds that can readily cross the membranes and gain access
to the classical ERs and GPER. Activation of ER by estrogen or environmental estrogens leads to
modulation of target gene transcription, which leads to cell proliferation and other pro-survival
cellular responses. Activation of GPER by estrogen or other estrogenic compounds (e.g. tamoxifen)
leads to the activation of heterotrimeric G proteins, which subsequently activate multiple
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downstream rapid signaling cascades including cAMP production, MAPK and PI3K activation
(through Src-dependent transactivation of EGFR). These rapid actions lead to several cellular
responses including cell proliferation and cell survival.

1.4.3 GPER-selective ligands
GPER and the classical ERs have overlapping signaling pathways. Therefore,
given their co-expression in many tissues, distinguishing which receptor is
mediating certain cellular responses within a given tissue has been challenging.
Selective ligands to the individual receptors (or to GPER versus the classical ERs)
would aid in better understanding the roles of the individual receptors. Ligand
specificity between estrogen receptor subtypes has been difficult to achieve with
regard to the classical estrogen receptors given their high degree of homology
within the ligand-binding pocket (previously discussed). Surprisingly, given the
large structural differences between the classical ERs (transcription factors) and
GPER (a GPCR), all currently evaluated ligands of the classical ERs, even PPT
(which was originally considered an ERα-selective compound), have been shown
to bind and either activate or inactivate GPER [23, 88]. Therefore, obtaining a
selective ligand to GPER or the ERs seemed unlikely. However, in 2006 Bologa et
al. [89] discovered a small GPER-selective ligand, termed G-1, which selectively
binds to GPER over the classical ERs, showing negligible activity towards the
classical ERs (Fig. 1.4). They showed that G-1 acts as a selective agonist of
GPER. A few years later Dennis et al. reported the successful conversion of G-1
into a GPER-selective antagonist, termed G15 [90], followed by the identification
of the even more selective GPER antagonist G36 [91], two years later. Lappano
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et al. later reported the identification of two GPER-selective agonists, termed
GPER-L1 and GPER-L2 [92], which have ~10-fold lower affinity for GPER versus
G-1 (Binding affinity of G-1 is 7-10 nM versus ~100 nM of GPER-L1 and
GPER-L2). Identification of GPER-selective compounds has made a great impact
on better understanding the role of GPER in various systems. To date G-1, G15
and G36 remain the most popular GPER-selective ligands, while truly ER-selective
ligands remain elusive.
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Figure 1.4. Structures of the GPER-selective agonist G-1 and the GPER-selective antagonists G15
and G36.

1.5 Estrogen and its role in breast cancer
Aside from its physiological role, estrogen also plays an important role in
disease, the most prominent being its role in breast cancer [10, 93]. Breast cancer
is the most commonly diagnosed cancer amongst women, with more than an
estimated 250,000 newly diagnosed cases of invasive breast cancer each year in
the United States [94]. There are four main subtypes of breast cancers: Luminal A
(characterized as being ERα+ and/or PR+ and negative for the human epidermal
growth factor receptor 2 (HER-2)), Luminal B (ERα+ and/or PR+, HER-2+/- with
high Ki-67 positivity), HER-2-enriched (ERα-, PR- and HER-2+) and triple negative
breast cancers (TNBCs, ERα-, PR- and HER-2-). Luminal A is the main type of
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clinically-observed breast cancer, with more than 70% of cases being classified as
this subtype [94]. Luminal A, Luminal B and HER-2-enriched subtypes can be
treated with targeted therapy against ERα (for Luminal A and Luminal B cases) or
HER-2 (for HER-2-enriched cases). TNBCs, which lack any of these molecular
targets are currently not treatable with targeted therapies and patients presenting
with this subtype have the worst prognosis (compared to the other 3 subtypes).
ERα is an important initiator and driver of breast cancer [95]. Due to its role
(exerting e.g. proliferative and survival signaling) and prevalence in the majority of
breast cancers (~70%), ERα has been an important molecular target for the
treatment of ERα-positive breast cancers for over 40 years [96, 97]. Inhibition of
ERα-signaling by endocrine therapy (also called anti-hormone therapy), using
selective estrogen receptor modulators (SERMs, such as tamoxifen), the selective
estrogen receptor downregulator (SERD) fulvestrant, and aromatase inhibitors
(AIs, such as letrozole and exemestane), has shown great clinical success in
treating ERα-positive breast cancers (discussed in the next section) [98, 99].

1.6 Breast cancer endocrine therapy
Endocrine therapy is effective at treating ERα-positive breast cancers and
has prolonged the lives of millions of women [98, 99]. It focuses on inhibiting the
growth of ERα-positive breast cancers by blocking the activation of the ERα, and
thus its downstream proliferative and pro-survival signaling. Endocrine therapy
achieves this either by directly blocking estrogen binding to ERα (using SERMs or
SERDs) or by decreasing the plasma levels of circulating estrogen by inhibiting its
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production (using AIs).

1.6.1 SERMs and SERDs
SERMs are a class of small molecules that act as antagonists of ERα by
competing with estrogen for binding to the receptor, thereby blocking the
recruitment of co-regulators to the receptor (Fig. 1.5) [100]. Their activity is tissue
specific, acting as ERα antagonists in the breast, while functioning as ERα
agonists in the bone and uterus [101, 102]. Currently Food and Drug
Administration (FDA)-approved SERMs include tamoxifen, raloxifene and
toremifene.
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Figure 1.5. Structures of the SERMs tamoxifen and its active metabolite 4-hydroxytamoxifen,
raloxifene, toremifene and the SERD fulvestrant (ICI182,780).

Tamoxifen (Nolvadex®, Soltamox®), the most prescribed SERM, has
shown great success in the clinic for both the treatment and prevention of ERαpositive breast cancers in pre- and post-menopausal women, showing a significant
decrease in ERα-positive breast cancer-related mortality and recurrence rates
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when taken over a 5 (and up to 10) year period [103, 104]. Unfortunately, due to
its agonist activity in the endometrium, women taking tamoxifen experience up to
a 7.5-fold increased risk of developing endometrial cancer [101, 105, 106]. Patients
taking tamoxifen also have an increased risk of developing thromboembolisms
[107, 108]. However, these risks do not tend to outweigh the benefits of the drug.
Compared to tamoxifen, raloxifene (Evista®) carries a lower risk of developing
thromboembolisms, but is less effective at preventing invasive breast cancer [109].
Nevertheless, raloxifene significantly decreases the risk of developing invasive
breast cancer in post-menopausal women with osteoporosis [110]. Raloxifene is
currently approved for the prevention of invasive breast cancer in post-menopausal
women

with

osteoporosis. The third

FDA-approved

SERM,

toremifene

(Fareston®), also increases the risk of developing thromboembolisms, but data
regarding its causal role in developing endometrial cancer is limited [111].
Toremifene is approved for the treatment of advanced ERα-positive breast cancers
in post-menopausal women. To date, tamoxifen is the only SERM approved for the
treatment of ERα-positive breast cancers in pre-menopausal women.
SERDs are a class of small molecules that, like SERMs, act as antagonists
of the ERα (Fig. 1.5). However, unlike SERMs, SERDs not only antagonize the
receptor, but also induce its degradation, due to destabilization of helix 12 in the
ER-LBD, resulting in destabilization of the entire protein and a decrease in ERα
protein levels [112]. Furthermore, SERDs are “pure” antagonists of the ERα, in that
they do not show agonist properties in other tissues [113]. Currently, fulvestrant
(Faslodex®) is the only FDA-approved SERD and is used for the treatment of
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metastatic ERα-positive breast cancers in post-menopausal women with disease
progression following prior endocrine therapies.

1.6.2 Aromatase inhibitors (AIs)
AIs are a class of small molecules that block the production of estrogen by
inhibiting the enzyme aromatase (CYP19A1) (Fig. 1.6) [114]. They have been
highly effective in the clinic for the treatment of ERα-positive breast cancers in
post-menopausal women [115]. In fact, they are more efficacious than tamoxifen
in this setting [99, 116]. However, this class of drugs has significant side-effects,
including muscle/joint pain, bone loss, hot flashes and insomnia, causing over 30%
of patients to discontinue treatment [117-119]. Nevertheless, AIs are highly
effective in the treatment of ERα-positive breast cancers and are becoming a more
popular standard first-line endocrine therapy option for post-menopausal women.
Currently FDA-approved AIs include the reversible AIs anastrozole (Arimidex®)
and letrozole (Femara®) and the irreversible AI, exemestane (Aromasin®).
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Figure 1.6. Structures of the aromatase inhibitors exemestane, anastrozole and letrozole.
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1.7 Endocrine resistance
Endocrine therapy is the standard of care for the treatment of ERα-positive
breast cancers and has been highly effective in the clinic. Unfortunately, some 30%
of patients eventually develop acquired endocrine resistance to the initial therapy,
with reports suggesting that this number may be as high as 40-50% [98, 120].
Several mechanisms have been proposed to account for the development of
endocrine resistance, including alterations in growth factor signaling (e.g.
overexpression of the EGFR or HER-2), changes in the expression of ERα or its
co-activators/co-repressors, mutations in ERα, changes in the metabolism of
tamoxifen and tamoxifen-induced GPER signaling (discussed later) [121-125].
In the late 1990s, Zhang et al. reported the identification of three ESR1 (the
gene encoding ERα) mutations in metastatic breast cancer samples [126]. One of
the mutations, Y537N, was found to cause constitutive activation of the receptor,
even in the absence of estrogen. More importantly, this mutation made the
receptor less sensitive to inhibition by tamoxifen (the maximum tested dose was
100 nM). This led to the proposal that mutations of this site could contribute to
breast cancer progression and endocrine resistance. Similar findings regarding
mutations at the Y537 codon were previously reported by Weis et al. in a structureactivity relationship study [127]. More recently, studies identified several ESR1
mutations in up to 55% of metastatic breast cancer samples of patients who
relapsed while on endocrine therapy [128-131]. Importantly, these mutations were
absent in the corresponding primary breast tumors and primary breast tumors in
general, pointing to a possible role in endocrine resistance. The most commonly
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occurring mutations were Y537S and D538G located in the ligand-binding domain
(LBD) of ERα. These mutations result in constitutive activation of the receptor by
inducing a ligand-bound confirmation of the receptor in the absence of estrogen.
More specifically, they stabilize helix 12, an important structural component in the
LBD of ERα, in a closed agonist-bound confirmation, thereby exposing a coregulator binding site on the receptor that is normally only revealed following the
binding of estrogen. This stabilized ligand-bound confirmation also makes the
mutant receptor less susceptible to inhibition by tamoxifen and fulvestrant, by
impairing access to the ligand binding pocket of the receptor [20, 128, 129]. These
observations support the role of these mutations in endocrine resistance in
response to not only AIs, but also SERM- and SERD-based therapies.
Interestingly, the Y537S mutation has been reported to be more resistant than the
D538G mutation, to in vivo inhibition by fulvestrant [132].
Clinical data of patients that have relapsed while on an AI therapy have
shown that the Y537S and D538G mutants are associated with more aggressive
relapse tumors [133]. This aggressive phenotype could be due to the unique
transcriptome induced by the Y537S and D538G mutants (compared to that of
wildtype ERα) that includes the modulation of pro-metastatic genes [134]. This
merits further research into genes that are specific targets of the mutant forms of
ERα, as potentially new therapeutic targets for the treatment of relapsed breast
tumors expressing mutant ERα. Interestingly, in a retrospective analysis of the
FERGI trial (a comparison of treatment with a PI3K inhibitor + fulvestrant versus
placebo + fulvestrant, in ERα-positive breast cancer patients with locally advanced
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or metastatic disease), Spoerke et al. did not observe a difference in the control
placebo + fulvestrant arm of the trial with respect to progression-free survival (PFS)
between patients harboring wildtype ESR1 versus patients harboring mutated
ESR1, as measured using circulating tumor DNA [135]. This underlines the
complexity of tumor heterogeneity and how the presence of other mutations
alongside ESR1 mutations could potentially influence ERα-targeted endocrine
therapies. Furthermore, it could imply that ESR1 mutations are more important in
endocrine resistance in a hormone-deprived setting (e.g. in patients on AI
therapies) than in tumors that relapse on SERM/SERD therapies. Nevertheless,
the presence and activity of mutant forms of ERα in the metastatic relapse setting
have become a highly studied resistance mechanism and are now strongly
considered in the development of next-generation SERMs and SERDs (discussed
in the next section).
Upregulation of positive regulators of the cell cycle (e.g. cyclins E1 and D1)
is another example of a mechanism involved in endocrine resistance [125]. This
mechanism leads to e.g. the activation of cyclin-dependent kinases (CDKs) that
counteract the anti-proliferative role of endocrine therapy by driving the cell through
G1 phase. This mechanism is heavily studied and is exemplified by the recent FDA
approval of three CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib) for the
treatment of metastatic breast cancer (in combination with endocrine therapies
such AIs or fulvestrant) [136]. For other resistance mechanisms, readers are
directed to comprehensive reviews on other mechanisms cited earlier in this
section.
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1.8 Next generation SERMs and SERDs
Acquired endocrine resistance is a major clinical problem in treating ERαpositive breast cancers. The presence of the Y537S and D538G ERα mutants in
many relapse tumors highlights the need for the development of improved SERMs
and SERDs that can effectively inhibit both the wildtype and clinically-observed
mutant forms of ERα [128-130]. Such new drugs could be effective in treating
relapse tumors harboring the mutant receptor and improve disease stabilization,
thereby prolonging the lives of patients.
Currently, for women with advanced metastatic ERα-positive breast cancer
that has relapsed while on endocrine therapy, therapeutic options are limited. In
this setting, the SERD fulvestrant has shown the most promising results in
extending PFS, either as a monotherapy or in combination with targeted therapies
like cyclin-dependent kinase 4/6 (CDK4/6) inhibitors [137, 138]. With regard to the
presence of ESR1 mutations, Fribbens et al. analyzed ESR1 mutations in baseline
plasma from the SOFEA trial (comparing exemestane versus fulvestrantcontaining therapies) and the PALOMA3 trial (comparing fulvestrant + placebo
versus fulvestrant + the CDK4/6 inhibitor palbociclib) [139]. They found that
fulvestrant provided a significant benefit over exemestane in patients with tumors
harboring ESR1 mutations. However, treatment with fulvestrant had a modestly
worse PFS outcome for patients with ESR1 mutations when compared to patients
with wildtype ESR1. The latter result is not surprising given that mutant forms of
ERα are less sensitive to fulvestrant and require higher drug concentrations to be
fully inhibited [128, 131, 132]. The currently approved dosage of fulvestrant (500

26

mg) has been shown to be ineffective in fully blocking ERα in tumors, and in turn
associated

with

early disease

progression

[140]. Taken

together, the

aforementioned observations imply that achieving higher plasma levels of
fulvestrant could be of great therapeutic benefit, especially with regard to relapse
tumors

harboring

ESR1

mutations.

Unfortunately,

fulvestrant

has poor

pharmacological properties, requiring it to be administered through painful,
monthly intramuscular injections, thereby limiting the maximum achievable dose
of the drug. As a consequence, the development of new, more bioavailable
SERMs/SERDs that possess better pharmacological properties, while also
efficaciously inhibiting ERα mutants, is the goal of much current research.
The small molecule ZB716, a boronic acid-modified version of fulvestrant
with high oral bioavailability, is an example of how improving the bioavailability of
a drug can lead to higher plasma levels (Fig. 1.7) [141-143]. Liu et al. showed that
ZB716 achieved over 10 times higher plasma levels than fulvestrant when orally
administered to mice and that ZB716 has similar levels of efficacy (compared to
fulvestrant) in vitro [141]. Similarly, Guo et al. showed that ZB716 achieved higher
plasma levels in both the blood and tumors in xenograft models [143]. The latter
study also demonstrated that ZB716 is more efficacious than fulvestrant in tumor
growth inhibition in a cell line-derived xenograft model. Interestingly, ZB716
displayed no observed benefit (versus fulvestrant) in inhibiting tumor growth in a
patient-derived xenograft (PDX) model.
Several new SERDs are currently being developed and assessed in clinical
trials to treat advanced endocrine-resistant breast cancers. AZD9496, an orally
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bioavailable SERD developed by AstraZeneca (Fig. 1.7), has been shown to be
highly effective at inhibiting ERα-positive breast cancer cells in vitro and in vivo,
while also being highly effective at binding and degrading wildtype and mutant
forms of ERα (the binding IC50 values for AZD9496 are >6-fold improved versus
those of fulvestrant) [144, 145]. Furthermore, Weir et al. showed that AZD9496
inhibited the growth of a PDX tumor harboring the D538G ERα mutant [145]. A
phase 1 clinical trial of AZD9496 was recently completed and indicated that the
drug is tolerated at the maximum tested dose (600 mg), even showing some early
signs of disease stabilization over a 12 month period [146].
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Another orally bioavailable SERD, G1T48, developed by G1 Therapeutics
Inc., is effective at inhibiting ERα-positive tumor growth in in vivo models of
tamoxifen and aromatase resistance [147]. Furthermore, G1T48 inhibits the
growth of ERα-Y537S- and ERα-D538G-expressing breast cancer cells. G1T48
also showed synergistic inhibition in a tamoxifen-resistant xenograft model when
used in combination with the novel CDK4/6 inhibitor, G1T38. G1T48 recently
entered a Phase 1 clinical trial (NCT03455270) for initial in-human safety testing
in women with advanced ERα-positive breast cancer.
Other

orally

bioavailable

SERDs,

including

LSZ102

(Novartis

Pharmaceuticals, NCT02734615), SAR439859 (Sanofi Inc., NCT03284957) and
GDC-0927 (Genentech Inc., NCT02316509) are also currently being evaluated
both in the lab and in clinical trials as potentially new therapeutic agents for the
treatment of advanced ERα-positive breast cancers [148-152]. Newly emerging
SERDs show promising results as potential ERα-targeting breast cancer therapies,
but only time will tell if any of these compounds are efficacious in patients and gain
clinical approval.
Aside from orally bioavailable SERDs, the already clinically-approved
SERM/SERD hybrid, bazedoxifene (Fig. 1.7), is also gaining more interest as a
potential therapeutic agent for treating ERα-positive advanced breast cancers.
Bazedoxifene, which is already used in hormone replacement therapy and for the
prevention of post-menopausal osteoporosis, exhibits favorable efficacy in various
endocrine-resistant breast cancer models [153-156]. Furthermore, Fanning et al.
reported that bazedoxifene inhibits the activity of the Y537S and D538G mutant
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forms of ERα, offering structural insights into its inhibitory mechanism [157]. Its
activity in models of endocrine resistance and its well tolerated drug profile, make
bazedoxifene a candidate that could prove efficacious in treating ERα-positive
breast cancers.

1.9 GPER: a culprit in endocrine resistance?

1.9.1 Implications for a role of GPER in endocrine resistance
The non-classical estrogen receptor, GPER, has gained attention as a
possible player in the development of endocrine resistance in breast cancer. This
theory stems from multiple clinical observations. Firstly, Filardo et al. reported that
GPER is expressed in over 60% of invasive breast cancers, with GPER positivity
correlating with a larger tumor size [158]. In the same study, they also observed
that GPER was co-expressed with ERα in ~40% of ER-positive invasive breast
tumors. GPER expression has also been found to be significantly higher in relapse
tumors of patients that had undergone prior tamoxifen therapy (compared to
matched primary tumors) [159, 160]. Furthermore, GPER expression has been
shown to correlate negatively with relapse-free survival, further indicating an
unfavorable role of the receptor in endocrine resistance [159]. Recently, Ignatov et
al. reported the opposite, finding a positive correlation between GPER-expression
and disease-free survival. However, this correlation was not statistically significant
[161]. Interestingly, they did report that treatment with tamoxifen was less
beneficial than an AI-based therapy in patients with GPER-positive breast tumors.
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In vitro data also supports the clinical observations that point to a negative
role for GPER in endocrine resistance. Ignatov et al. showed that tamoxifeninduced proliferation of tamoxifen-resistant MCF-7 cells could be abrogated by
downregulation of GPER [124]. Similar findings were reported by Mo et al. who
showed that GPER-inhibition, using the GPER-selective antagonist G15 [90],
could “re-sensitize” tamoxifen-resistant cells to tamoxifen [160]. Tamoxifeninduced proliferation, via a GPER-mediated pathway, has also been observed in
other cell types [83, 162].
Some elucidation for a role of GPER in endocrine resistance came from
Catalano et al. who showed that tamoxifen-resistant MCF-7 cells expressed higher
levels of aromatase [163]. Increased aromatase expression could potentially
create a local increase in estrogen levels, thereby allowing tumors to overcome
the inhibitory effects of tamoxifen and AI therapies. Importantly, the increased
aromatase expression could be reverted back to baseline levels by reducing GPER
expression or inhibiting its function using G15.
Zekas et al. also provided a potential mechanism for GPER in endocrine
resistance [164]. They observed that tamoxifen and fulvestrant, through a GPERmediated pathway, induce the translocation of the pro-apoptotic transcription
factor Forkhead box protein O3a (FOXO3a) out of the nucleus. Nuclear expulsion
of FOXO3a is a phenotype that is associated with its inactivation and promotes a
pro-survival state [165-167]. Importantly, knockdown of GPER abrogated the
observed ligand-induced translocation of FOXO3a. It was suggested that
tamoxifen-induced inactivation of FOXO3a could provide a fraction of tumor cells
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with a survival advantage to overcome inhibitory effects of tamoxifen mediated
through ERα, eventually leading to the acquisition of endocrine resistance through
mutations.
An important observation linking GPER to endocrine resistance was
provided by Mo et al. [160]. They reported that a tamoxifen-resistant MCF-7 tumor
could be “re-sensitized” to tamoxifen treatment of mice with a combination of
tamoxifen and G15. Importantly, mono-therapy with either tamoxifen or G15 had
no effect on tumor growth. This implies that pro-survival signaling by GPER
(through its downstream target Akt) is possibly overcoming the tamoxifen-induced
apoptotic signaling (via ERα), a consequence of tamoxifen-mediated activation of
GPER (discussed in the next section).
The body of scientific data pointing to a role for GPER in endocrine
resistance has been met with some contradictory reports. A small number of
publications have reported that activation of GPER, using the GPER-selective
agonist G-1, induces cell death of breast cancer cells [89, 168, 169]. Whether this
cell death is caused by hyperstimulation of GPER or is a possible off-target effect
due to the high doses of G-1 tested, remains unclear and warrants further
investigation. Nevertheless, these findings do not diminish the numerous
observations implying a pro-survival role for GPER in endocrine resistance.

1.9.2 A proposed role for GPER in endocrine resistance and how to
circumvent it
SERMs and SERDs are widely used to inhibit ERα signaling in breast
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cancers. However, contrary to their antagonism towards ERα, currently approved
SERMs (tamoxifen and raloxifene) and SERD (fulvestrant) have been shown to
act as agonists of GPER in breast cancer cell models, resulting in the activation of
the ERK and PI3K pathway [72, 75, 88]. Similarly, many other estrogenic
compounds (e.g. xenoestrogens and phytoestrogens) that act on the classical ERs
have also been found to act as agonists of GPER [23].
This cross-activation of GPER, particularly by tamoxifen, is a common
element seen in all of the observations discussed in the previous section and is a
potential clue into the role of GPER in the development of endocrine resistance
[124, 160, 163]. In the case of tamoxifen, patients are treated for a minimum of 5
years with cancer relapse often occurring after completion of this 5 year period
[98]. It is possible that chronic activation of GPER by tamoxifen, promotes longterm survival of a fraction of primary tumor cells or alternatively breast cancer stem
cell. This prolonged survival could grant this subset of tumor cells sufficient time to
acquire additional mutations, resulting in resistance to the primary therapy (e.g.
acquiring endocrine-resistant ESR1 mutations) and leading to the development of
endocrine-resistant relapse tumors (Fig. 1.8). This possible role highlights the
potentially significant benefit of developing truly ERα-selective therapeutic
antagonists that do not cross-activate GPER. A truly ERα-selective antagonist
would lack cross-activation of GPER and its resulting pro-survival signaling, thus
potentially delaying or decreasing the development of endocrine-resistant relapse
tumors.
At this time, no truly ERα-selective compounds (agonists or antagonists)
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have been identified in the literature. The current development of next-generation
SERDs as focused on the compound’s growth inhibitory potential in models of
endocrine resistance, yet none have been assessed for their potential
cross-activity towards GPER. Although these new compounds look promising,
harboring cross-activity towards GPER could limit their long-term efficacy in
treating ERα-positive advanced breast cancers. This emphasizes the potential
benefit of truly ERα-selective antagonists. It is worth noting that to date one
compound, termed MIBE, has been reported to act as an antagonist towards both
the ERα and GPER [170]. However, its efficacy has not yet been assessed in
models of endocrine resistance.

Figure 1.8. Proposed role of GPER in the development of endocrine resistance. Tamoxifen (as
well as other SERMs and SERDs) inhibits its molecular target (ERα) (red line), but simultaneously
cross-activates GPER (green arrow). This cross-activation induces the downstream activation of
Akt and other survival signals. Chronic cross-activation of GPER by tamoxifen (over the course of
the average 5 year tamoxifen regimen) provides a subset of primary tumor cells with prolonged
survival signaling that opposes the inhibitory cell death induced through the tamoxifen-mediated
inhibition of ERα. Prolonged survival thus provides this subset of surviving primary tumor cells
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sufficient time to acquire additional mutations that lead to resistance to the primary therapy,
resulting in the development of endocrine-resistant relapse tumors.

1.10 Summary
Estrogen plays a role in many physiological processes and it exerts its effect
through three known estrogen receptors: ERα, ERβ and GPER. While it is known
that the receptors share overlapping signaling pathways, it has been challenging
to understand the roles of the individual receptors, in a given system co-expressing
GPER and ERα or ERβ, due to a lack of selective ligands to the individual
receptors. The majority of currently evaluated ER ligands, including clinically used
ER antagonists (such as tamoxifen and fulvestrant), have been shown to be
cross-selective towards GPER, acting as either an agonist of GPER [23]. To date,
selective agonists and antagonists of GPER, lacking cross-selectivity towards the
ERs have been identified, but truly ER-selective ligands have remained elusive.
In breast cancer, GPER is hypothesized to contribute to the development
of and endocrine resistance due to its cross-activation by SERMs and SERDs.
This cross-reactivity of clinically used ER antagonists (in particular tamoxifen)
towards GPER, and the resulting activation of downstream pro-survival signals,
highlights the potential benefit of truly ER-selective antagonists for the treatment
of ER-positive breast cancers.
In this dissertation work we address these dilemmas by firstly searching for
a truly ER-selective ligand that lacks GPER selectivity in Chapter 2. We identify a
small molecule, termed AB-1 that acts as an ER-selective agonist, activating only
ERα/β transcriptional activity while acting as an antagonist of rapid ERα/β
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signaling. Importantly, we show that AB-1 does not bind or activate GPER. In
Chapter 3 we identify a truly ER-selective antagonist, termed AB-82P, following
structural modification of AB-1. We show that AB-82P inhibits ER activity in vitro
and is effective in multiple cell line models of endocrine resistance.
Taken together, this dissertation work identifies a novel class of
ER-selective ligands that lack cross-selectivity towards GPER. These newly
identified small molecules could be utilized to gain a better understanding of the
roles of the classical ERs (versus that of GPER) in health and disease. More
importantly, AB-82P could serve as the structural basis for the development of
new, truly ERα-selective antagonists for the treatment of ERα-positive breast
cancers and potentially decrease or delay the development of endocrine
resistance.
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2.1 Abstract
Estrogen exerts extensive and diverse effects throughout the body of
women. In addition to the classical nuclear estrogen receptors (ERα and ERβ),
the G protein-coupled estrogen receptor GPER is an important mediator of
estrogen action. Existing ER-targeted therapeutic agents act as GPER agonists.
Here, we report the identification of a small molecule, named AB-1, with the novel
activity of high selectivity for binding classical ERs over GPER.

AB-1 also

possesses a unique functional activity profile as an agonist of transcriptional
activity but an antagonist of rapid signaling through ERα. Our results define a novel
class of small molecules that discriminate between the classical ERs and GPER,
as well as between modes of signaling within the classical ERs. Such an activity
profile if developed into an ER antagonist could represent an opportunity for the
development of first-in-class nuclear hormone receptor-targeted therapeutics for
breast cancer exhibiting reduced acquired and de novo resistance.
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2.2 Introduction
Estrogens (predominantly 17β-estradiol, E2) regulate multiple diverse
aspects of physiology throughout the body, particularly during development,
puberty and reproduction, but also in metabolic, endocrine, cardiovascular,
nervous, musculoskeletal and immune functions[5]. Although many of these
effects are traditionally associated with women, E2 also has important roles in male
physiology [4]. As a result of these varied actions, targeting E2 pathways has been
exploited extensively in the development of therapeutic and preventative
approaches [171]. For example, E2 and its derivatives have been used for over a
half a century as the primary constituent of contraceptive pills [172].
E2 and its receptors also play important roles in both health and disease,
particularly breast cancer development and treatment. In addition to the classical
nuclear estrogen receptors (ERα and ERβ), the 7-transmembrane spanning G
protein-coupled estrogen receptor GPER (previously GPR30) has become
recognized as an important mediator of E2 action [23, 173-177]. Although many
of the effects of E2 are mediated by ERα and ERβ through transcriptional
regulation, rapid signaling pathways (e.g. kinase activation, such as ERK1/2 and
Akt, cAMP production and ion fluxes) that occur in the time frame of seconds to
minutes are now understood to be activated by both ERα [178] and GPER [173].
Pharmacological approaches have identified families of compounds for breast
cancer therapy as well as for managing symptoms of menopause (including
osteoporosis) termed selective estrogen receptor modulators and downregulators
(SERMs, such as tamoxifen and raloxifene, and SERDs, such as fulvestrant,
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respectively) [56, 179], based on their (tissue-dependent, in the case of SERMs)
transcriptional activities assumed to occur exclusively through ERα; however,
tested SERMs and SERDs lack selectivity with respect to GPER, functioning as
GPER agonists [72, 75, 88]. In fact, a broad array of xenoestrogens, including
synthetic (industrial, agricultural and pharmacological) and natural (phyto- and
myco-estrogens), have been shown not only to bind GPER but also to function as
GPER agonists [23, 71, 74]. This lack of ER/GPER pharmacological discrimination
led us and others to seek novel compounds with the ability to selectively modulate
GPER activity, in the absence of ERα/β activity [89-92]. The most widely used
GPER-selective ligands are the tetrahydroquinolines G-1 [89] (an agonist), G15
[90] and G36 [91] (both antagonists). G-1 mediates or reproduces many of the
salutary effects of E2, particularly those associated with rapid signaling, in rodent
models of multiple sclerosis [180, 181], stroke [182, 183], cerebral ischemia
following cardiac arrest [184], traumatic brain and spinal cord injury [185, 186],
myocardial infarction [187], atherosclerosis [188], obesity [175], diabetes [189],
pancreatic islet survival [190] and transplantation [191], hypertension [192, 193],
and diastolic dysfunction [194], among others [23, 174]. In contrast, the GPER
antagonists G15 and G36 have been shown to have important applications in
carcinogenesis [88, 160, 195] and cardiovascular aging [196], the latter through
the regulation of NADPH oxidase-mediated superoxide production [197].
A similar lack of pharmacological selectivity towards the classical estrogen
receptors ERα/β and against GPER has resulted in important experimental and
clinical challenges. This is evident as the result of unexpected agonist activities of
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both SERMs and SERDs via GPER in both experimental systems [75, 88, 164,
198, 199] and clinical use of the SERD ICI182,780 (fulvestrant) as an anti-hormone
therapy for advanced breast cancer in women where, for example, symptomatic
hypotension is a common side effect [200], consistent with the GPER-mediated
vasodilatory activity of ICI182,780 observed ex vivo [201]. There is also evidence
suggesting that the acquired resistance observed in women treated with antiestrogens (SERMs and SERDs) for prolonged periods may result in part from
chronic activation of GPER [159, 160, 202], potentially through the inactivation of
the pro-apoptotic transcription factor Foxo3a [164].
Here we present the discovery of the first truly ER-selective ligand that lacks
binding and activity towards GPER, defined as a selective ligand for estrogen
receptor proteins (SLERP). We employed a combination of computational and
biomolecular screening to identify AB-1, an oxabicyclic compound that binds both
ERα and ERβ with similarly high affinity but lacks binding to GPER. Due to the
absence of binding to GPER, rapid signaling via GPER is expectedly absent;
however, although transcriptional activity via ERα is virtually identical to that of E2,
AB-1 surprisingly lacks the ability to initiate multiple rapid signaling events via ERα.
Thus, in addition to discriminating between ERα and GPER, AB-1 also
discriminates between the transcriptional (genomic) and signaling (non-genomic)
activities of ERα, providing the complementary activity profile to compounds that
elicit extra-nuclear signaling but not transcriptional activity through ERα [203].
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2.3 Results
Employing computational and virtual screening of a 10,000 compound
GPCR-optimized library, we previously identified the GPER-selective agonist G-1
[89], the GPER-selective antagonist G15 [90] and subsequently optimized the
even more selective antagonist, G36 [91], as compounds that lack ERα/β-binding
(Fig. 2.1). The discovery of these GPER-selective compounds has facilitated a
better understanding of the physiological roles of GPER in E2 signaling [23, 204].
To further distinguish the roles of ERs and GPER in E2 signaling, we sought to
expand our repertoire of selective compounds, this time screening for compounds
harboring an inverse profile to that of our GPER-selective compounds (i.e. high
selectivity for binding ERα/β over GPER). Employing high-throughput flow
cytometry-based biomolecular screening with ERα-GFP- and ERβ-GFPexpressing COS7 cells and the fluorescently labeled E2 derivative E2-Alexa633
as previously described [89], we screened the top 100 virtual hits of our compound
library for selective binding activity towards ERα and ERβ. We identified one
compound, a phenol-substituted oxabicyclo[3.3.1]nonene, hereafter termed AB-1
(Fig. 2.1), that competed with E2-Alexa633 binding to ERα and ERβ.
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Figure 2.1. Chemical structure of estrogen (17β-estradiol, E2), GPER-selective ligand G-1 and
ER-selective ligand AB-1.
O

HN

N
H

O

S
NH

Br
HO2C

O
O

N

S
NH

Br
HO2C

N
HO2C

HN

N
H

CO2H

N
N

CO2H

N

N

O
O

42

To validate the activity and confirm the chemical identity of our primary hit,
we synthesized AB-1 (4-(5-(hydroxymethyl)-8-methyl-3-oxabicyclo[3.3.1]non-7en-2-yl))-phenol) [205, 206], following a modified procedure employing a
hafnium(IV) triflate catalyzed Prins cyclization [207] (see Supplemental
Methods). The compound was fully characterized and was identical to previously
reported NMR spectra with characteristic 1H NMR signals observed for the C8methyl ( 1.01, 3H) and benzylic hydrogen at C2 ( 4.50, 1H) [206]
(Supplementary Fig. 1).
To confirm our findings and examine selectivity with respect to GPER, we
co-expressed ERα-GFP or ERβ-GFP with GPER-mRFP1 in COS7 cells, incubated
the cells with E2-Alexa633, and imaged by confocal microscopy. Because ERα/β
and GPER localization is mutually exclusive, with ERα/β in the nucleus and GPER
in the endoplasmic reticulum (i.e. cytosolic), selectivity of E2-Alexa633 binding can
be assessed through spatial co-localization with each receptor (Fig. 2.2a). In cells
expressing ERα-GFP and GPER-mRFP1, E2-Alexa633 is localized to both ERα
and GPER (Fig. 2.2a, top row). Addition of E2 blocked binding of E2-Alexa633
to ERα-GFP (and ERβ-GFP, not shown) as well as GPER (GPER-mRFP1) (Fig.
2.2a, second row), whereas addition of AB-1 blocked the binding of E2-Alexa633
to both ERα-GFP and ERβ-GFP, but not to GPER-mRFP1 (Fig. 2.2a, third and
fourth rows). To characterize the binding properties of AB-1 in greater detail, we
determined its binding affinity to the individual ERs (Table 1.1). Using a flow
cytometry-based competitive binding assay with transiently transfected COS7
cells, we determined that AB-1 blocked E2-Alexa633 binding to ERα and ERβ with
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IC50 values of 3 nM and 26 nM, respectively (Fig. 2.2b-c). IC50 values for E2 were
0.3 nM and 0.6 nM for ERα and ERβ, respectively. Importantly, AB-1 did not
significantly block E2-Alexa633 binding to GPER at concentrations up to 10 μM

Figure 2.2. Ligand-binding properties of AB-1. (a) COS7 cells co-expressing ERα-GFP or ERβGFP with GPER-mRFP1 were stained with E2-Alexa633 in the presence or absence of unlabeled
E2 (100 nM) or AB-1 (1 μM). AB-1 blocks the binding of E2-Alexa633 to ERα and ERβ, but not
to GPER. Confocal images are representative of three independent experiments. White scale bar
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represents 10 μm. Data are from three independent experiments. (b-d) Binding affinities of E2 and
AB-1 for ERα, ERβ and GPER. Competitive ligand binding assays were performed using 2 nM
E2-Alexa633 and the indicated concentrations of unlabeled E2 (■) or AB-1 (▲) in COS7 cells
transfected with either ERα-GFP (b), ERβ-GFP (c) or GPER-GFP (d). Data are mean ± s.e.m. from
three independent experiments.

(Fig. 2.2d). Binding affinities to the purified ligand binding domain (LBD) of ERα
and ERβ were also determined employing a TR-FRET-based competitive binding
assay, revealing IC50 values for ERα and ERβ LBDs of 38 nM and 24 nM,
respectively (with IC50 values for E2 of 0.26 nM and 0.47 nM for ERα and ERβ,
respectively) (Supplementary Fig. 2.2 and Table 2.1). Taken together, these
results show that AB-1 selectively binds to ERα and ERβ, but not GPER.
To assess the functional properties of AB-1, we first examined its effect on
ER-mediated transcription in MCF-7 cells stably expressing an ERE-GFP reporter
gene [208]. Like E2, AB-1 dose-dependently induced ERE activation with an EC50
value of ~15 nM (vs. ~0.08 nM for E2) (Fig. 2.3a). To expand upon its
transcriptional activity, we also assessed the effect of AB-1 on global ER-mediated
gene transcription compared to that of E2 in MCF-7 cells. Interestingly, AB-1
induced an almost identical transcription profile (both in terms of activation and
inhibition) to that of E2 (Fig. 2.3b, r=0.94, p<0.0001), with two of the best
characterized E2/ER-stimulated genes (Progesterone Receptor and GREB1)
showing virtually identical levels of upregulation, implying that AB-1 functions as
an ER transcriptional regulator that activates and inhibits expression of ER-target
genes similar to that of E2. Interestingly, a small number of the most E2/ERrepressed genes (e.g. PSCA, MYCN and FAM65C) were repressed to a lesser
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extent by AB-1 compared to E2, although other genes repressed by about 8-10fold by E2 were similarly repressed by AB-1.
E2

AB-1

ERα cell binding (IC50)
ERβ cell binding (IC50)

0.30 nM
0.65 nM

3 nM
26 nM

ERα LBD binding (IC50)

0.26 nM

38 nM

ERβ LBD binding (IC50)

0.47 nM

24 nM

GPER cell binding

~8 nM

>> 10 μM

ERE expression (EC50)

0.08 nM

15 nM

MCF-7 proliferation (EC50)

0.3 pM

0.5 nM

ERα protein degradation (%)

54 %

52 %

Calcium signaling ERα (IC50)

-

33 nM

Calcium signaling ERβ (IC50)

-

75 nM

Uterine Imbibition (EC50)

~3 ng

~90 μg

Uterine Proliferation (EC50)

~5 ng

~30 μg

Table 2.1. Summary of AB-1 properties

To further confirm the agonist nature of AB-1, we tested its ability to induce
MCF-7 cell growth, which is not only induced by ER activation, but also dependent
on it. AB-1 stimulated cell growth to a similar (in fact, slightly greater) maximal
extent compared to E2, with an EC50 of ~0.5 nM (vs. ~0.3 pM for E2) (Fig. 2.3c).
Upon binding of both agonists and antagonists (classical SERDs), ERα protein
undergoes degradation and ultimately downregulation of its steady state levels
[209]. Therefore, to determine whether AB-1 exerts the same effect as E2 on ERα
stability and protein levels, we treated MCF-7 cells with E2, AB-1, the SERM 4hydroxytamoxifen (4-OHT), which stabilizes ERα, or the SERD fulvestrant
(ICI182,780), which potently downregulates ERα. AB-1 induced a ~50% decrease
in ERα levels, similar to that of E2, whereas 4-OHT and ICI182,780, as expected,
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moderately increased and potently decreased ERα levels, respectively (Fig. 2.3d
and Supplementary Fig. 2.3) [209]. Together, these data demonstrate that AB-1
acts as an agonist of ERα/β transcriptional activity, stimulating MCF-7 cell growth
and inducing ERα degradation.

Figure 2.3. Transcriptional activity of AB-1. (a) Ligand-induced expression of GFP in MCF-7
cells. MCF-7 cells stably expressing an ERE-GFP reporter were stimulated with the indicated
concentrations of E2 (■) or AB-1 (▲) and GFP expression was measured by flow cytometry. Data
indicate mean ± s.e.m. of four independent experiments. (b) Ligand-induced global ER-mediated
gene transcription profile. MCF-7/WS8 cells were stimulated with 1 nM E2 or 1 μM AB-1 and
gene expression was assessed in duplicate. Gene expression changes of 1231 genes (greater than
1.5 fold) are shown as average log2 fold-change compared to vehicle-treated cells for E2 (x-axis)
and AB-1 (y-axis). Expression of GREB1 and PGR are shown with arrows. Correlation factor (R)
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was 0.94 with a p-value <0.0001. (c) Effect of AB-1 on MCF-7 cell growth. MCF-7 cells were
stimulated with the indicated concentrations of E2 (■) or AB-1 (▲) and total cell numbers were
analyzed after 5 days. Cell numbers are shown as percentages relative to E2-treated cells (100%).
Data points are mean ± s.e.m. of three independent experiments each performed in triplicate. (d)
Ligand-induced protein degradation of ERα. MCF-7 cells were cultured with the indicated
compounds and ERα levels determined by Western blot. Data is normalized to DMSO-treated
samples and is shown as mean ± s.e.m. of at least 4 independent experiments. ***p<0.001 vs.
DMSO by one-sample t-test.

To determine whether AB-1 mediates rapid signaling as observed for E2,
we examined the PI3K/Akt-mediated inactivation of Foxo3a in MCF-7 cells [164].
Foxo3a is a forkhead box transcriptional activator of pro-apoptotic genes in the
absence of survival factors. Growth factors (e.g. EGF) that stimulate the PI3K
pathway lead to the Akt-mediated phosphorylation of Foxo3a, which in turn leads
to its translocation to the cytoplasm and subsequent proteasomal degradation. To
evaluate Foxo3a localization, we employed a Foxo3a-GFP construct that was
transiently expressed in MCF-7 cells. Following EGF stimulation, Foxo3a
translocated from the nucleus to the cytoplasm (Fig. 2.4a). E2 and the GPERselective agonist G-1 also stimulated cytosolic translocation, although in a lower
percentage of cells (Fig. 2.4b). In contrast, AB-1 had no effect on Foxo3a
translocation, nor did it alter the extent of E2- or G-1-mediated translocation (Fig.
2.4b). This result is in fact consistent with our previous observations that the E2mediated activation of PI3K and Akt, leading to Foxo3a inactivation, is mediated
by GPER.
In order to determine whether AB-1 can also mediate E2-dependent rapid
signaling specifically via the classical estrogen receptors, we employed COS7 cells
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Figure 2.4. Ligand-induced intracellular translocation of FOXO3a. (a) Intracellular localization of
FOXO3a-GFP. MCF-7 cells transiently expressing FOXO3a-GFP were treated with vehicle (Ctl),
E2 (10 nM), G-1 (100 nM), AB-1 (1 μM), EGF (50 ng/mL) or a combination of AB-1 + E2 or AB1 + G-1 and FOXO3a-GFP localization determined by confocal microscopy. Data are
representative of three independent experiments. (b) Quantification of data in (a) and represent the
mean ± s.e.m. of at least 3 independent experiments. *p<0.05 vs. vehicle (Ctl) by one-way ANOVA
with Bonferroni post-hoc test.

expressing either ERα, ERβ or GPER. We first examined the ability of AB-1 to
induce calcium mobilization. Surprisingly, unlike E2, which induced rapid calcium
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mobilization in COS7 cells expressing ERα, ERβ or GPER (Fig. 2.5a), AB-1 did
not induce calcium mobilization in any of these cells (Fig. 2.5b). More importantly,
AB-1 dose-dependently inhibited E2-mediated calcium mobilization in COS7 cells
expressing either ERα (IC50 = 33 nM) or ERβ (IC50 = 75 nM) (Fig. 2.5c), but did not
block E2-mediated calcium mobilization in GPER-expressing COS7 cells (Fig.
2.5b). This result suggests that despite acting as an agonist of transcriptional
activation via ERα, AB-1 acts an antagonist or inverse agonist of ER-mediated
rapid calcium signaling.
Despite E2-dependent PI3K/Akt activation in MCF-7 cells being mediated
by GPER, we have previously shown that E2 can mediate PI3K activation by both
classical estrogen receptors (ERα and ERβ) and GPER in transfected COS7 cells
[72]. Thus, to determine whether the inhibitory effect of AB-1 on rapid calcium
signaling extends to other rapid signaling pathways, we next examined whether
AB-1 could regulate PI3K activation in COS7 cells transfected with either ERαGFP, ERβ-GFP or GPER-GFP. Cells were co-transfected with the PH-mRFP1
reporter, which contains the PIP3-binding pleckstrin homology (PH) domain of Akt
fused to a red fluorescent protein and thus translocates to sites of PI3K activity
and PIP3 accumulation [72]. Employing this system, we observed that E2 induced
strong nuclear localization of the PH-mRFP1 reporter in COS7 cells expressing
ERα, ERβ or GPER (Fig. 2.5d, second row), indicative of PI3K activation, as
previously reported [72]. However, unlike E2, AB-1 did not induce nuclear
translocation of the PH-mRFP1 reporter in COS7 cells expressing ERα, ERβ or
GPER (Fig. 2.5d, third row). Furthermore, AB-1 was again able to block
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E2-mediated signaling via ERα and ERβ, but not through GPER (Fig. 2.5d,
bottom row). Together, the calcium and PI3K signaling results not only further
confirm the binding selectivity of AB-1 for ERα and ERβ vs. GPER, but more
importantly and surprisingly, they reveal that AB-1 acts as an antagonist of rapid
signaling via the classical estrogen receptors ERα and ERβ.
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Figure 2.5. AB-1 antagonizes classical ER-mediated rapid signaling. (a-c) Ligand-induced effect
on intracellular calcium mobilization through individual ERs. COS7 cells transiently expressing
ERα-GFP (red curve), ERβ-GFP (blue curve) or GPER-GFP (green curve) were stimulated with
either 1 nM E2 (a) or 1 μM AB-1 followed by 1 nM E2 (b). Intracellular calcium mobilization was
evaluated using indo1-AM and ligands were added at 20 s or 80 s as indicated. Data is shown as
the relative 490nm/400nm ratio change (y-axis) compared to mock-transfected COS7 cells (black
curve) and re representative of three independent experiments. (c) Intracellular calcium
mobilization dose-response curves for E2-stimulated COS7 cells expressing ERα-GFP (▲) or
ERβ-GFP (■), treated with the indicated concentrations of AB-1. Data indicate mean ± s.e.m. of
three independent experiments. (d) AB-1 antagonism of PI3K activation through ERα and ERβ.
COS7 cells co-expressing PH-mRFP1 and either ERα-GFP (left panel), ERβ-GFP (middle panel)
or GPER-GFP (right panel) were stimulated with vehicle (DMSO), 1 nM E2, 1 μM AB-1 or a
combination of E2 + AB-1. PI3K activation was assessed by the translocation of the PH-mRFP1
reporter from the cytoplasm to the nucleus as exemplified by E2 treatment of ERα and ERβexpressing cells. Confocal images are representative of three independent experiments.

In vivo assessment of compound estrogenicity has traditionally been carried
out employing the uterotrophic assay, based on highly E2-dependent actions in
the uterus. Upon E2 depletion in mice, typically through ovariectomy, the uterus
regresses with the epithelium entering a non-proliferative state and the uterine
losing electrolytes and water, resulting in substantial weight reduction. Treatment
with E2 for 1-3 days leads to an acute stimulation of proliferation within the uterine
epithelium and an increase in overall weight due to water uptake, termed
imbibition. To investigate the estrogenic effects of AB-1 in vivo, we evaluated the
uterotrophic effects of AB-1 compared to E2. Whereas E2 yielded a strong
imbibition response at a dose of 10 ng (with an EC50 estimated between 2 and 10
ng), AB-1 displayed imbibition only at a dose of 91 μg (with an almost 2-fold
increase in uterine wet weight over that of sham-treated mice), with no effect at
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doses of 2 and 10 μg, suggesting an EC50 in the 50-90 μg range (Fig. 2.6a). We
also examined the effect of AB-1 on the proliferative response of uterine epithelial
cells in the same mice used for the uterotrophic assay. AB-1, at the highest dose
tested, induced an almost 12-fold increase in epithelial proliferation (measured as
Ki-67 positive staining) vs. sham-treated mice, similar to the response observed
with 10 ng E2 (Fig. 2.6b). Together, these results demonstrate that AB-1
stimulates multiple murine uterine effects associated with the activities of ERα,
though with less potency compared to E2.

Figure 2.6. Estrogenic effects of AB-1 in the mouse uterus. (a) Ligand-induced effect on mouse
uterine weight. Ovariectomized mice were treated with vehicle (sham) or the indicated amounts of
E2 or AB-1 for 18 h and body weights and uterine wet weights determined. Uterine weights are
shown as ratios to total body weights (mean ± s.e.m.). (b) Uterine epithelial cell proliferation. Fixed
uterine sections from samples in (a) were assessed for epithelial cell proliferation by staining for
Ki-67 expression. Data are the mean ± s.e.m. of 3 mice per group; *p<0.05 vs. sham by one-way
ANOVA with Bonferroni post-hoc test.
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2.4 Discussion
Our understanding of E2 signaling has evolved over the last half century,
from the earliest cellular studies of rapid signaling responses [210, 211], to the
subsequent appreciation of its transcriptional regulation through ERα and later
ERβ. With the discovery of GPR30 as an additional estrogen receptor (leading to
its designation as GPER) that mediates many of the rapid signaling events in
response to E2, the landscape of E2 signaling mediators became more
complicated.

Pharmacological approaches have traditionally been critical in

unravelling the roles of individual receptor subtypes within a family. In the case of
the classical ERs and GPER, this approach has been complicated by the high
degree of overlap in ligand specificity [17]. Not only are the ligand binding pockets
of ERα and ERβ highly homologous, but to date all tested ER-binding compounds
exhibit binding and/or activity towards GPER [23]. This is particularly true of the
family of SERMs and SERDs, which despite generally inhibiting activity of the
classical ERs, act as agonists of GPER. Studies of GPER were facilitated with the
identification of the highly selective GPER agonist G-1 [89] and soon thereafter
GPER antagonists (G15 and G36) [90, 91], all of which exhibit little to no activity
towards the classical ERs. Unfortunately, compounds with the inverse selectivity,
i.e. binding to ERs but not GPER, have to date not been identified. In this report,
we described the identification of the first such compound AB-1, that binds with
high affinity to both ERα (and ERβ) but not to GPER, defining AB-1 as a novel
SLERP.
Pharmacological selectivity between the two classical estrogen receptors
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(ERα and ERβ) has been difficult to achieve, largely due to the extremely high
sequence and structural conservation of the ligand binding pockets of these two
receptors.

Following decades of optimization, the most highly ERα-selective

compound PPT (PPT) exhibits only about 400-fold selectivity for ERα over ERβ
[65]. Despite this, PPT has been shown to lack selectivity for ERα against GPER,
where it acts as an agonist [88]. Thus, based on the fact that to date all tested ERα
ligands bind to or activate GPER [23], one might speculate that achieving ERα
selectivity vs. GPER might be extremely difficult. This is in contrast to the high
selectivity (>105 fold) of the GPER-selective agonist G-1 for GPER over ERα [91],
which is believed to be due to the fact that G-1 is slightly larger than E2 [89],
precluding its occupancy of the ligand binding pocket of ERα or ERβ while allowing
its binding to the presumably slightly larger or conformationally more
accommodating ligand binding pocket of GPER.
Although “bulky” bicyclic compounds may seem like a poor substitute for
the planar E2 molecule, the ability of bicyclic compounds, such as
bicyclo[3.3.1]nonanes,

to

function

as

ER

ligands

was

reported

by

Katzenellenbogen in 2003 [212]. Compounds of the oxabicyclo[3.3.1]nonene
structural class were first identified as ER ligands through screening campaigns
carried out by multiple independent groups in the mid-2000s. In 2003, Sibley et al.
at Bayer AG, identified AB-1 (termed compound 2) in a primary screen as an ER
ligand [205]. In 2005, Hamann et al. at Ligand Pharmaceutical again identified AB1 (compound 3) in a primary screen [206] and in 2006 Hsieh et al. reported the
characterization of AB-1 (termed OBCP-1M) identified from a high-throughput
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functional screen of the ChemBridge 10,000-compound chemical library (San
Diego,

CA)

[213].

Thus,

the

inclusion

of

compounds

with

the

oxabicyclo[3.3.1]nonene scaffold has been a recurring occurrence in the design of
chemical libraries, perhaps due to its structural rigidity. Interestingly, our virtual
screen for similarity to E2 ranked AB-1 as 53rd, whereas G-1 was ranked as 92nd
of the 10,000 compounds in our GPCR-optimized library. Thus, both compounds
fell within the top 1% of the library in terms of E2 “similarity”, despite that fact that
they display inverse properties with respect to ER and GPER selectivity.
The previous three reports identifying AB-1 as an ER ligand were published
prior to the wide acceptance of GPER as an E2 receptor; as a consequence, no
evaluation of GPER selectivity, either in terms of binding or function, was
performed.

Furthermore, none of the reports examined rapid signaling

mechanisms such as those observed for E2. Selectivity of ERα vs. ERβ was
however examined. Hamann et al., reported, based on transcriptional reporter
assays, a 2-fold difference in EC50 of racemic AB-1, favoring ERβ over ERα [206].
Whereas the (+) and (-) isomer displayed similar EC50 values for ERβ, similar to
the (-) isomer for ERα, the (+) isomer displayed a 20-fold worse EC50 for ERα.
Hsieh et al. also observed a selectivity for ERβ employing racemic AB-1, both in
terms of binding to purified ER ligand binding domain (~10-fold selectivity) and
function (transcriptional reporter assays, ~60-fold) [213]. Interestingly, in
permeabilized whole cell ligand binding assays, we observed comparable binding
of AB-1 to ERα and ERβ (Table 2.1).
Our results demonstrate an exceptionally high correlation between the gene
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expression profiles of E2 and AB-1 in MCF-7 cells. Given the lack of rapid signaling
observed for AB-1, this would suggest that rapid signaling has a minimal impact
on ERα-mediated transcriptional activity. In contrast, downregulation of ERK2 (via
siRNA) has been shown to alter the gene expression profile of E2 in MCF-7 cells
[214], suggesting a role for MAPK signaling in transcriptional activity of ERα. In the
same study, ERK2 expression was also shown to be critical for E2-mediated MCF7 cell proliferation. In our gene expression study, MCF-7 cells were deprived of
E2 for a total of 4 days prior to stimulation with either E2 or AB-1 for 24 hours.
Under these conditions, basal levels of ERK2 activity are expected to be
decreased but perhaps not to the same extent as in the presence of ERK2
knockdown, suggesting that basal ERK2 activity may be sufficient to support E2mediated regulation of transcription. Finally, the high concordance between E2and AB-1-mediated transcriptional regulation suggests that the conformation of
ERα induced by AB-1 is very similar to that of E2, resulting in the similar
recruitment of co-activators and co-repressors.
The ability of E2 to mediate rapid (i.e. non-genomic) signaling has been
known for over 50 years, from early studies of E2-mediated cAMP production and
calcium (45Ca) mobilization [210, 211], to the resurgence of interest in such
pathways in the 1990s [215, 216]. Multiple approaches have been employed over
the years to investigate mechanisms of rapid E2-mediated signaling, including the
generation of mutant forms of ERα (e.g. membrane- or nuclear-targeted forms of
the receptor) [178] and pharmacological approaches employing novel ligands,
such as large E2-dendrimers (that cannot pass the plasma membrane) [217] and
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small molecule PaPEs (pathway preferential estrogens) that exhibit exceptionally
low affinity for ERα, resulting in activation of non-genomic signaling but not
transcriptional activity [203]. The advent of GPER-selective ligands further
enhanced our understanding of rapid E2-mediated signaling events in multiple cell
types and tissues by selectively activating or inhibiting GPER in the absence of ER
activity [23]. Now, for the first time, we have identified a truly ER-selective
compound that displays no binding affinity or activity towards GPER, enabling
studies of ER-specific activities in the absence of GPER signaling. Furthermore,
the selective profile of AB-1 with respect to ER activity, activating transcription
while precluding ER-mediated rapid signaling, provides additional selectivity that
will further our understanding of ER function. It should be noted that we only
examined two aspects of ER-specific rapid signaling, namely calcium mobilization
and PI3K activation, limiting our conclusions to these pathways. Because the
mechanisms of ER-mediated signaling are in general poorly understood, it is
possible that other aspects of rapid signaling may be preserved. Nevertheless, the
ability of AB-1 to regulate ER-mediated gene expression in an almost identical
manner to E2, while having no effect on GPER-mediated signaling, represents a
novel pharmacological profile.
There has been mounting evidence that GPER expression and activation
by currently employed anti-estrogens, particularly tamoxifen, play an important role
in resistance to these drugs, as suggested by the poor prognosis of breast cancer
patients treated only with tamoxifen [159], increased GPER expression in breast
cancer patient biopsies following tamoxifen treatment [159], enhanced GPER
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signaling in tamoxifen-resistant MCF-7 cells [202], inhibition of tamoxifen-resistant
breast cancer cell growth by GPER antagonists [160] and improved survival of
MCF-7 cells in the presence of G-1 [164]. Based on such results, the development
of highly ER-selective antagonists that lack GPER cross-reactivity could be of
significant clinical benefit, lowering the occurrence of resistance seen with current
anti-estrogen therapies.
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2.5 Materials and methods
Cell culture and transfection. Cell lines were obtained from the American Type
Culture Collection. Cells were cultured in the stated medium supplemented with
10% FBS, 2 mM L-glutamine, 100 units/mL penicillin and 100 μg/mL streptomycin.
Transient transfection experiments were performed 24 h after seeding cells using
Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. The
expression plasmids have been previously described [72]. For E2 deprivation, cells
were grown for 24-48 h (with intermediate changes of medium) in phenol red-free
medium lacking serum or supplemented with 10% charcoal-stripped FBS, both of
which were further supplemented with 2 mM L-glutamine, 100 units/mL penicillin
and 100 μg/mL streptomycin.

Virtual Screening. A database containing structures of 10,000 molecules
(CDLDB) provided by Chemical Diversity Labs Inc (San Diego, CA), to which 17βestradiol was added, was processed as described previously [218]. Briefly, using
17β-estradiol as reference point, 2D-based similarity coefficients were computed
employing both Daylight and MDL fingerprints using Tanimoto’s symmetric
distance-between-patterns [219] and Tversky’s asymmetric contrast model [220].
We also obtained 3D shape similarity coefficients using the Tanimoto [219] and
Tversky [220] formulae using Rapid Overlay of Chemical Structures [221]. An
additional pharmacophore-based 3D similarity metric was derived from ALMOND
descriptors [222]. The combined similarity score attributed 40% weighting to 2D
fingerprints, 40% to the shape-based similarities and 20% to pharmacophore-
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based similarity. Given this composite score, the top 100 ranked molecules were
selected for physical screening employing a fluorescent whole cell ligand-binding
assay.

Chemical Synthesis. G-1 was synthesized as previously described [223]. The
compound AB-1 (4-(5-(hydroxymethyl)-8-methyl-3-oxabicyclo[3.3.1]non-7-en-2yl))-phenol) has been reported previously [205, 206], and was synthesized by a
modified procedure [207] and obtained as a diastereomerically pure, racemic
mixture of enantiomers. Compound identity was verified by comparison of high
field 1H NMR (500 MHz) spectra to published values [206], and purity was
demonstrated by quantitative analytical HPLC chromatography to be >98%. Full
experimental details and spectroscopic data confirming the identification of AB-1
are provided in the supplementary section (Appendices A and B).

Ligand-binding assays. Binding assays for ERα, ERβ and GPER were performed
as previously described [72]. Briefly, COS7 cells were transiently transfected with
ERα-GFP, ERβ-GFP or GPER-GFP. Following serum starvation for 24 h, cells
(~5x104) were incubated with competitor for 20 min prior to addition of an equal
volume of 4 nM E2-Alexa633 in saponin-based permeabilization buffer. Following
10 min at 25 C, cells were washed once with PBS/2%BSA. For flow cytometric
analysis, cells were resuspended in 20 µL and 2 μL samples were analyzed on a
DAKO Cyan flow cytometer using HyperCyt™ as described [224]. For confocal
microscopy, cells were stained as above and fixed with 2% PFA in PBS containing
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1 mM CaCl2 and 1 mM MgCl2 for 15 min, washed, mounted in Vectashield and
analyzed immediately by confocal microscopy using a Zeiss LSM510 confocal
fluorescent microscope.

Intracellular calcium mobilization. COS7 cells transfected with ERα-GFP, ERβGFP or GPER-GFP (5 x 106 cells) were incubated at room temperature in HBSS
containing 5 M indo1-AM and 0.05% pluronic acid for 30 min. Cells were then
washed once with HBSS and resuspended in HBSS at a density of 10 7cells/mL.
Ca++ mobilization was determined ratiometrically using ex 340 nm and em 400/490
nm at 37C in a spectrofluorometer (QM-2000-2, Photon Technology International)
equipped with a magnetic stirrer and heated sample chamber. The relative
490nm/400nm ratio is plotted as a function of time.

PI3K activation. The PIP3-binding domain of Akt fused to mRFP1 (PH-mRFP1)
was employed to assess cellular PIP3 production and localization as described
[72]. Briefly, COS7 cells (co-transfected with PH-mRFP1 and either ERα-GFP,
ERβ-GFP or GPER-GFP) were plated on coverslips and serum starved for 24 h
followed by stimulation with ligands as indicated for 15 min. The cells were fixed
with 2% PFA in PBS, washed, mounted in Vectashield and analyzed by confocal
microscopy using a Zeiss LSM510 confocal fluorescent microscope.

ER-ERE transcription. ER activity via EREs was determined using MCF-7 cells
stably transfected with an ERE-GFP reporter construct [208] as previously
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described [91]. Briefly, cells were deprived of E2 for 4 days (with one intermediate
medium change) in phenol red-free DMEM/F12 supplemented with 10% charcoalstripped FBS. Cells (~80,000) were seeded in 24 well plates, and 24 hours later
treated with the indicated compounds (dissolved in DMSO, 0.1% final) for 24 hours
in triplicate, trypsinized, washed and analyzed for green fluorescence by flow
cytometry. Mean fluorescence intensities of gated live cells were determined and
normalized to E2 values following subtraction of vehicle control values.

Gene expression analysis. MCF-7/WS8 cells, provided by Craig Jordan (MD
Anderson), were cultured in RPMI supplemented with 10% FBS, 2 mM Lglutamine, non-essential amino acids, antibiotic/antimycotic and 6 ng/ml of
insulin. E2 depletion was carried out by culturing cells in E2-depleted medium with
daily medium changes for three days. Cells were seeded sparsely (2x10 6 cells per
15 cm dish) in E2-depleted medium and treated the following day with 1 nM E2, 1
μM AB-1 or DMSO (vehicle control) for 24 hours. Final DMSO concentrations were
0.01%.

Total RNA was isolated using QIAGEN RNeasy minikits following

homogenization using QIAshredders and employing the direct lysis protocol for cell
monolayers. Total RNA (500ng) was reverse transcribed using a T7 Oligo(dT)
primer, followed by second strand synthesis and purification of the double stranded
cDNA. In vitro transcription was performed on this product using a mix of
biotinylated nucleotides to generate biotin labeled cRNA as described
(Ambion/Applied Biosystems Illumina Total Prep RNA Amplification Kit). cRNA
samples were hybridized to the BeadChip array, washed, stained with
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C3-strepavidin following the manufacturer’s protocols (Illumina). The BeadChip
was scanned and data analyzed using the Genome Studio Gene Expression
Module (Illumina). Samples were normalized using a rank invariant normalization.
Missing data were imputed, and Benjamini and Hochberg false discovery rate
calculations were applied. The DMSO controls were used as reference samples
and the Illumina custom error model was employed.

Cell proliferation. MCF-7 cells were grown in E2-depleted medium for 4 days
(with one intermediate medium change) in phenol red free DMEM/F12
supplemented with 10% charcoal-stripped FBS. Cells were seeded in 96 well
plates at low density, and 24 hours later treated with the indicated concentrations
of compounds (dissolved in DMSO, 0.1% final) for 3-5 days in triplicate. Cell
growth was determined by Alamar Blue staining.

ERα degradation. MCF-7 cells were seeded (500,000 cells/well) in 6-well plates
in complete culture medium. The following day, cells were transferred to medium
containing charcoal-stripped serum for 48 h (with one intermediate change of
medium) and subsequently treated with the indicated compounds (0.01% DMSO
final) for 24 h. Cells were washed once with ice-cold PBS, lysed in RIPA buffer (50
mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 1% Na-deoxycholate
and 0.1% SDS) containing 50 mM NaF, 1 mM Na3VO4 and protease cocktail (1x)
and passed through a 20G needle (10-16 times). Lysates were cleared by
centrifugation (13,000 rpm for 15 min at 4˚C) and protein concentrations
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determined using the Pierce™ BCA Protein Assay Kit. Samples (20 ug) were
resolved by SDS-PAGE (4-12% Bis-Tris gel), transferred to nitrocellulose
membranes and subjected to Western blot analysis. Membranes were probed
overnight with a rabbit anti-ERα antibody (Cell Signaling, 1:1000) in 4% BSA-TBST
at 4˚C followed by a secondary HRP-linked goat anti-rabbit antibody (1:5000) for
1 h at RT. Bands were visualized by chemiluminescence. To detect actin,
membranes were stripped (30 min at RT) and probed with a mouse anti-actin
antibody (Millipore, 1:5000) for 1 h at RT followed by a secondary HRP-linked goat
anti-mouse antibody (1:2500) for 1 h at RT. Bands were quantified using ImageJ
software (NIH).

FOXO3a translocation. FOXO3a localization assays were performed as
described [164]. Briefly, MCF-7 cells were seeded on 12 mm coverslips in a 24well plate one day before transfection. Cells were transfected with 0.3 μg FOXO3aGFP using the Lipofectamine 3000 reagent (Invitrogen) according to the
manufacturer’s protocol. Twenty-four hours post-transfection, cells were serum
starved for 24 h prior to treatment. Cells were fixed in 2 % PFA, washed with PBS
and mounted in Vectashield on coverslips. Coverslips were imaged on a Zeiss
LSM800 microscope and localization determined from 10 fields per condition.

Mouse uterine estrogenicity. C57Bl6 female mice (Harlan) were ovariectomized
at 10 weeks of age. E2 and AB-1 were dissolved in absolute ethanol at 1 mg/mL
and diluted in ethanol. For treatment, 10 μL of diluted E2 or AB-1 was added to
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90 μL aqueous vehicle (0.9% NaCl with 0.1% albumin and 0.1% Tween-20).
Ethanol alone (10 µL) was added to 90 μL aqueous vehicle as control (sham).
Twelve days post-ovariectomy, mice were injected subcutaneously at 5:00 pm with
100 μL sham, E2 or AB-1. Eighteen hours after injection, mice were killed, weighed
and uteri removed and weighed (normalizing to body weight) after the
mesometrium and any attached adipose tissue was trimmed away. Uteri were
then fixed in 4% paraformaldehyde, and embedded in paraffin.

Five-micron

sections were placed on slides, and proliferation in uterine epithelia was
quantitated by immunofluorescence using anti-Ki-67 antibody (LabVision) followed
by goat anti-mouse IgG conjugated to Alexa488 (Invitrogen).

Nuclei were

counterstained with 4',6-diamidino-2-phenylindole (DAPI). At least 4 animals per
treatment were analyzed, and the Ki-67 immunodetection was repeated three
times per mouse. Percent Ki-67 positive cells = (number of Ki-67 positive cells /
total number of DAPI-stained luminal epithelial cells) x 100 for three different fields
per sample.

Statistical analyses. Data were analyzed by one-way analysis of variance
(ANOVA) followed by Bonferroni’s post-hoc test, by two-tailed, unpaired Student’s
t-test or by one-sample t-test as appropriate. Non-linear regression curves were
determined using a variable slope fit. Values are expressed as mean ± s.e.m.; n
equals the number of assay replicates or animals used. Statistical significance was
accepted at a P value < 0.05. All analyses were carried out using Prism version
5.0 for Macintosh, GraphPad Software.
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3.1 Abstract
Endocrine therapy has shown tremendous success for the treatment of
estrogen receptor (ER)-positive breast cancers for over 40 years, with tamoxifen
being a widely used first-line therapeutic drug option. Unfortunately, many women
on tamoxifen and similar anti-hormone therapies develop resistance to these
agents. Cross-reactivity of these drugs to the G protein-coupled estrogen receptor
(GPER), is thought to contribute to this clinically observed resistance. This
highlights the need for truly ER-selective antagonists that lack cross-reactivity to
GPER. Here, we describe the identification of a small molecule, termed AB-82P,
that has the unique property of acting as an ER antagonist while lacking activity
towards GPER. AB-82P defines a new class of ER antagonists and could serve as
the structural basis for the development of truly ER-selective antagonists for the
treatment of ER-positive breast cancers; potentially improving patient outcomes by
decreasing the overall development of endocrine resistance in breast cancer in
patients.
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3.2 Introduction
Estrogen (mainly E2) plays an important role in many physiological systems
including the female reproductive, the cardiovascular, and the immune systems [5,
19, 175]. It exerts its function through the classical estrogen receptors, ERα and
ERβ, and the 7-transmembrane spanning G protein-coupled estrogen receptor
(GPER, formerly GPR30) [16, 72, 225]. The classical ERs are mainly responsible
for E2-mediated transcriptional signaling, whereas GPER mainly exerts
E2-mediated rapid, non-genomic signaling, such as ERK1/2 and Akt activation [17,
226]. Estrogen also plays a role in disease, exemplified by its role in breast cancer
development and progression [95]. In many breast cancers (~70%), estrogen
exerts proliferative and survival signaling through ERα, making it critical in the
growth of ERα-positive tumors [96]. This has made ERα an important therapeutic
target in breast cancer therapy for over 40 years [97].
Endocrine therapy, using selective estrogen receptor modulators (SERMs,
such as tamoxifen), downregulators (SERDs, such as fulvestrant) and aromatase
inhibitors which block the synthesis of E2, has shown great success in the clinic
for the treatment of ERα-positive breast tumors, having prolonged the lives of
millions of breast cancer patients [98, 99]. Until recently, SERMs, tamoxifen in
particular, have been a popular first-line therapy, alongside aromatase inhibitors
(in post-menopausal women), in treating ERα-positive breast cancers, but the
SERD fulvestrant (ICI182,780, typically used in metastatic relapse cases) has
been gaining traction as a first-line therapy due to the potent therapeutic efficacy
of SERDs [227, 228].
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Tamoxifen is one of the most widely used endocrine therapies for treating
ER-positive breast cancers and is the most prescribed SERM. Unfortunately,
patients taking tamoxifen often relapse with tamoxifen-resistant tumors during or
following the completion of the standard 5-year regimen [98, 120]. Moreover, about
a third of patients do not respond initially to the therapy due to de novo resistance.
Several mechanisms have been described to contribute to the development of
acquired endocrine resistance, including the development of endocrine-resistant
ERα mutants (e.g. the Y537S and D538G mutants) [121-123]. One mechanism, in
particular, that has been proposed to contribute to the development of tamoxifen
resistance is thought to be chronic tamoxifen-induced activation of GPER [124,
160]. Tamoxifen, an ERα antagonist, has been shown to cross-activate GPER in
breast and other cell types, leading to the activation of the proliferative and
pro-survival factors ERK1/2 and Akt [72, 75, 88, 162]. In ERα-positive breast
tumors, this cross-activation of GPER (and subsequent activation of survival
pathways), is hypothesized to oppose the pro-apoptotic signals induced by the
inhibitory effects of tamoxifen (via ERα), thereby potentially prolonging the survival
of a subset of breast cancer cells. This prolonged survival may lead to the eventual
acquisition of tamoxifen-resistant mutations (including the ERα Y537S) and
development of tamoxifen-resistant relapse tumors (Pepermans and Prossnitz in
review). Importantly, many other SERMs and SERDs, including raloxifene and
fulvestrant, have also been shown to cross-activate GPER in breast cancer cells
[23]. Clinical data also supports the role of GPER as a contributor to the
development of endocrine resistance. Ignatov et al. reported higher levels of GPER
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expression in relapse tumors (compared to matched primary tumors) of patients
that had undergone prior treatment with tamoxifen versus GPER expression levels
observed in relapse tumors of patients that had not undergone prior tamoxifen
therapy [159]. Together these observations highlight the potential need for the
development of new SERMs and SERDs that inhibit ERα yet do not cross-activate
GPER.
Here we describe the identification of a small ligand, termed AB-82P, that
acts as a truly selective antagonist of the classical ERs (ERα and ERβ), while not
showing any cross-activity towards GPER. Employing molecular modeling of the
previously identified ER-selective transcriptional agonist, AB-1 (Revankar, Bologa,
Pepermans, Sharma et al. in review) in the ligand binding domain (LBD) of ERα
and its X-ray structure [213], we identified a site on AB-1 that, following the addition
of an alkyl chain, converted the ligand to an antagonist (AB-82P) of the classical
ERs, while maintaining its non-reactivity towards GPER. We show that AB-82P
binds to the classical ERs while not inducing rapid GPER-mediated signaling.
Furthermore, AB-82P blocks E2-mediated ERα transcriptional activity and induces
degradation of both the wildtype and the Y537S mutant form of ERα. Lastly, we
show that AB-82P exhibits growth inhibitory properties in wildtype MCF-7 cells and
two cell line models of endocrine resistance.
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3.3 Results
GPER is implicated in the development of tamoxifen resistance in breast
cancer, possibly through its cross-activation by tamoxifen. This highlights a
therapeutic benefit for truly ER-selective antagonists. Currently, no ER-selective
antagonists exist that lack cross-reactivity towards GPER. Therefore, we sought
to identify compounds that harbor such properties. We previously identified the
ER-selective agonist, AB-1, by high-throughput screening (manuscript under
review). Employing molecular modeling, using the crystal structure of AB-1 bound
to the ERα-LBD (PDB 2B1V, termed OBCP-1M) and the crystal structure of the
ERα antagonist ICI164,384 bound to rat ERβ-LBD (PDB 1HJ1), we observed that
the methyl group at carbon-8 of AB-1 protruded out of the ERα-LBD at a site similar
to the carbon-tail of ICI164,384 (Fig. 3.1, red arrow) [213, 229]. We hypothesized
that the addition of an alkyl chain at this position would convert AB-1 into an ER
antagonist while maintaining its selectivity for the classical ERs over GPER. To
test this, we synthesized an AB-1 derivative, termed AB-82P, with an alkyl chain
attached at the carbon-8 position of AB-1 (Fig. 3.1 and Supplementary Fig. 3.1).

Figure 3.1. Chemical structure of estrogen (E2), the ER-selective agonist AB-1 and the
ER-selective ligand AB-82P. Red arrow indicates carbon-8 position of AB-1.
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Figure 3.2. Ligand-binding properties of AB-82P. (a) Binding affinities of AB-82P for ERα and
ERβ. GST-tagged ERα-LBD (●) or ERβ-LBD (■) was incubated with 3 nM fluorescently-labeled
E2 analogue in the presence of the indicated concentrations of AB-82P. Competitive binding was
assessed by TR-FRET by labeling the ER-LBDs with an electron donor, terbium-labeled antibody.
(b) Ligand-induced activation of ERK. Hec50 cells were treated with the indicated compounds for
15 min and phosphorylated ERK levels were assessed by Western blot analysis and normalized to
the DMSO-treated samples. Data are mean ± s.e.m. of three independent experiments.

To determine whether the addition of the alkyl chain resulted in AB-82P
becoming a selective ER antagonist, we first assessed whether it still bound to the
classical ERs. Employing a TR-FRET-based competitive binding assay, purified of
ERα-LBD and ERβ-LBD were incubated with a fluorescent E2 analogue and
increasing concentrations of AB-82P. AB-82P dose-dependently blocked binding
of the fluorescent E2 analogue to both the ERα-LBD and the ERβ-LBD with IC50
values of 0.22 μM and 1.8 μM, respectively (Fig. 3.2a). Next, we tested whether
AB-82P shows any activity towards GPER by assessing its ability to induce
GPER-mediated ERK activation. We treated Hec50 cells, which express GPER
but neither ERα or ERβ, with E2, the GPER-selective agonist G-1, AB-82P or a
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combination of E2 or G-1 with AB-82P [89]. While both E2 and G-1 increased ERK
activity in the cells, AB-82P had no effect on ERK activity. More, importantly,
AB-82P did not affect E2- or G-1-induced activation of ERK, implying that AB-82P
does not bind or have activity towards GPER (Fig. 3.2b). Together these data
show that the addition of the alkyl chain to AB-1 did not alter the ER-binding
selectivity of the molecule and that AB-82P selectively binds to the classical ERs,
but not to GPER.
Next, we assessed the functional properties of AB-82P. First, we
determined its ability to induce ER-mediated ERE activation in MCF-7 cells stably
expressing an ERE-GFP reporter gene [230]. Whereas E2 dose-dependently
induced ER-mediated ERE activation (EC50≈ 30 pM), AB-82P did not induce ERE
activation up to the maximum tested dose (5 μM) (Fig. 3.3a). Similarly, the ERα
antagonists, 4-hydroxytamoxifen (4-OHT, the active form of tamoxifen) and
fulvestrant (ICI), at 1 μM, did not induce ERE activation. To examine whether
AB-82P could block E2-induced ERE activation, we treated the cells with
increasing doses of AB-82P in the presence of E2. AB-82P dose-dependently
blocked E2-mediated ERE activation with an IC50 of 2 μM, which is ≈1000-fold
higher than that of 4-OHT and ICI (IC50 values for 4-OHT and ICI were both 3 nM)
(Fig. 3.3b). These data indicate that AB-82P acts as an antagonist of the classical
ERs. To expand upon its transcriptional reporter activity, we tested whether
AB-82P could block E2-mediated transcription of known ERα target gene by
qRT-PCR. MCF-7 cells were treated with E2, AB-82P or a combination of the two
and RNA levels of TFF1, GREB1 and progesterone receptor (PGR) were
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measured. AB-82P alone did not induce gene transcription of TFF1, GREB1 or
PGR. In fact, AB-82P induced a slight decrease in TFF1 and GREB1 transcript
levels, possibly due to residual E2 in the charcoal-stripped medium (Fig. 3.3c).
Importantly, AB-82P blocked E2-induced transcription of these target genes. ICI
was used as a control inhibitor and showed strong inhibition of E2-induced gene
transcription at a 5-fold lower concentration than AB-82P.

Figure 3.3. Transcriptional activity of AB-82P. (a-b) Ligand-induced expression of GFP in MCF-7
cells. MCF-7 cells stably expressing an ERE-GFP reporter were treated with the indicated
concentrations of E2 (●), AB-82P (■), ICI (▲) or 4-OHT (▼) and in the absence (a) or presence
(b) of 100 pM E2 and GFP expression was assessed by flow cytometry. Data are mean ± s.e.m. of
three independent experiments. (c) Ligand-induced expression of ERα target genes. MCF-7 cells
were treated with the indicated compounds and gene expression of TFF1, GREB1 and PGR were
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assessed. Data are mean ± s.e.m. of at least three independent experiments. *p<0.05 and **p<0.01
vs. DMSO by one-sample t-test. #p<0.0001 vs. E2 by one-way ANOVA with a Bonferroni’s posttest. (d) Effect of AB-82P on MCF-7 cell growth. MCF-7 cells were treated with the indicated
concentrations of AB-82P in the absence (●) or presence (■) of 100 pM E2. Cell viability was
assessed after 5 days. Cell viability was normalized to corresponding DMSO-treated cells. Dashed
lines indicate inhibitory levels of 1 μM 4-OHT and 1 μM ICI in the presence of 100 pM E2.

Transcriptional signaling by ERα is crucial for MCF-7 cell growth. Therefore,
we next determined whether AB-82P could inhibit AB-82P cell growth. MCF-7 cells
were treated with increasing concentrations of AB-82P and cell viability was
assessed. AB-82P dose-dependently inhibited growth of MCF-7 cells with an IC50
value of ≈8-μM (Fig. 3.3d, black curve). AB-82P also inhibited E2-mediated cell
growth of MCF-7 cells (IC50 value ≈4.2 μM) (Fig. 3.3d, red curve). 4-OHT and ICI
were used as control inhibitors in the presence of E2 (Fig. 3.3d, dotted lines).
Together, these data reveal that AB-82P acts as a selective antagonist of the
classical ERs and inhibits MCF-7 cell growth. Thus, addition of the alkyl chain to
the carbon-8 position of AB-1 converted the molecule from an ER-selective
transcriptional agonist to an ER antagonist, while maintaining reactivity to the
classical ERs over GPER.
The field of ERα antagonists has recently been largely focused on
developing new SERDs, rather than SERMs, for the treatment of ER-positive
breast cancers due to the greater efficacy of SERDs over SERMs in inhibiting ERα
activation. This is primarily due to ligand-induced degradation of ERα by SERDs,
but not by SERMs. Therefore, we examined whether AB-82P acts as a SERD or
a SERM. MCF-7 cells were treated with E2, AB-82P, or ICI and ERα protein levels
were measured. E2 induced >40% decrease in ERα levels, which is a known
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mechanism responsible for terminating ERα signaling following its activation by E2
(Fig. 3.4a) [209]. Like ICI, AB-82P induced strong ERα degradation (>80% for

Figure 3.4. AB-82P induces degradation of ERα. (a) Ligand-induced degradation of ERα. MCF-7
were treated with the indicated compounds and ERα protein levels were assessed by Western blot
(top panel). Actin served as a loading control (bottom panel). Quantification of the western blot is
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shown on the right. Data are mean ± s.e.m. of at least three independent experiments. **p<0.01,
***p<0.001 and ****p<0.0001 vs. DMSO. (b) Dose-dependent degradation of ERα. MCF-7 cells
were treated with the indicated concentrations of AB-82P or ICI (top panel) and ERα protein levels
were assessed by Western blot. Quantifications of the corresponding blots (bottom panel) are mean
± s.e.m. of three independent experiments. (c) Ligand-induced proteasomal degradation of ERα.
MCF-7 cells were treated with the indicated compounds in the absence (top panel) or presence
(bottom panel) of the proteasome inhibitor MG-132 and ERα protein levels were assessed by
Western blot. Cells were either pre-treated with DMSO or MG-132 for 1 h before ligand stimulation
(in the presence of DMSO or MG-132). Blots are representative of three independent experiments.

AB-82P and ≈70% for ICI), albeit at a 10-fold higher concentration than ICI. To
better compare the potency of AB-82P versus ICI, at inducing ERα degradation,
cells were treated with increasing concentrations of either compound. We found
an EC50 value of 1.9 μM for AB-82P versus 0.6 nM for ICI, which was expected
given the higher affinity of ICI for the receptor (Fig. 3.4b).
Degradation of ERα occurs through a proteasome-mediated pathway. To
examine the ERα degradation pathway mediated by AB-82P, we treated MCF-7
cells with E2, AB-82P or ICI in the presence or absence of the proteasome
inhibitor, MG-132. Whereas, AB-82P induced strong ERα degradation in the
absence of MG-132, MG-132 completely blocked the observed ligand-induced
degradation of the receptor (Fig. 3.4c). Furthermore, MG-132 similarly blocked
both E2- and ICI-induced degradation of the receptor. Together, these data
indicate that AB-82P acts as a SERD and induces strong ERα degradation through
a proteasome-mediated pathway.
Endocrine resistance in breast cancer is a serious clinical issue and
understanding the mechanisms responsible for its development is an intensely
studied area of research. Several resistance mechanisms, including the
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emergence of constitutively active, endocrine-resistant ERα mutants (e.g. Y537S),
have been described [121, 130]. Therefore, new SERMs and SERDs need to be
efficacious against endocrine-resistant tumors, in general, but also specifically
against clinically relevant mutant forms of ERα. We therefore sought to assess the
efficacy of AB-82P in cell line models of endocrine-resistance. First, we examined
whether AB-82P could degrade the clinically relevant ERα-Y537S mutant. HEK293
cells, transiently expressing a HA-tagged ERα-Y537S construct, were treated with
AB-82P or ICI and protein levels of the ERα mutant were assessed. AB-82P
reduced HA-ERα-Y537S levels by ≈40%, which is about half the efficiency
observed for degrading wildtype ERα (compared to >80% degradation for wildtype
ERα) (Fig. 3.5a). ICI, showed a comparable decrease in mutant ERα protein levels
to those of AB-82P, albeit at a 10-fold lower concentration. Next, we tested whether
AB-82P

could

inhibit

Tamoxifen-resistant

cell

MCF-7

growth
cells

of

tamoxifen-resistant

(TamR)

were

treated

MCF-7
with

cells.

increasing

concentrations of AB-82P or 4-OHT and cell viability was assessed. AB-82P
dose-dependently inhibited TamR cell growth, although maximum inhibition was
not reached at the highest tested dose (Fig. 3.5b, black curve). As expected,
4-OHT did not inhibit TamR cell growth (Fig. 3.5b, red curve). However, slight
inhibition was observed at 5 μM 4-OHT. Lastly, we tested the ability of AB-82P to
inhibit growth of a long-term estrogen-deprived (LTED) MCF-7 cell line (a model
for aromatase inhibitor resistance). MCF-7 LTED cells were treated with increasing
concentrations of AB-82P or ICI. Both AB-82P and ICI dose-dependently inhibited
the growth of MCF-7 LTED cells with IC50 values of 2.3 μM and 0.3 nM,
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respectively (Fig. 3.5b, green and blue curves). Importantly, AB-82P was able to
achieve a greater overall level of growth inhibition than ICI, though at much higher
concentrations. Together these data demonstrate that AB-82P, at sufficiently high
concentrations, can degrade the ERα-Y537S, albeit to a lesser extent than that
observed for degradation of wildtype ERα and is effective at inhibiting cell growth
in different cell line models of endocrine resistance.

Figure 3.5. Inhibitory effects of AB-82P in cell line models of endocrine resistance. (a)
AB-82P-induced degradation of ERα-Y537S. HEK293 cells transfected with the HA-ERα-Y537S
mutant were stimulated with the indicated compounds and HA-ERα-Y537S protein levels were
assessed by Western blot. Blots are representative of three independent experiments. Quantification
of the blots are shown to the right panel. *p<0.05 vs. DMSO. (b) TamR (●) and MCF-7 LTED (▲)
cells were treated with the indicated concentrations of AB-82P, 4-OHT (for TamR) (■) or
ICI182,780 (for MCF-7 LTED) (▼) and cell viability was assessed after 5 days. Data are mean ±
s.e.m. of three independent experiments. Cell viability was normalized to corresponding
DMSO-treated cells.
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3.4 Discussion
Breast cancer is the most common type of cancer among women, with over
250,000 new cases per year in the United States alone [94]. The majority (>70%)
of these cancers are driven by ERα, which has led to the development of potent
ERα-targeted endocrine therapies. Tamoxifen, which was originally developed as
a female contraceptive, has been one of the most utilized forms of endocrine
therapy since the late 1970s [231]. It has maintained its popularity despite the
development of potent aromatase inhibitors, one reason being its potent efficacy
accompanied by well-tolerated side-effects [104]. Although tamoxifen represents
an effective endocrine therapy for primary ER-positive breast cancers, women
often develop recurrent disease, presenting at relapse with tamoxifen-resistant
tumors. Ignatov et al. showed that relapse tumors in women that were treated with
tamoxifen have a statistically significant increase in GPER expression compared
to their matched primary breast tumors [159]. Similar observations were made by
Mo et al. in a separate cohort of women [160]. This observed increase in GPER
expression in relapse tumors is consistent with multiple findings that tamoxifen acts
as an agonist of GPER and therefore may contribute to the development of
tamoxifen resistance [88, 124, 160, 162]. Women are usually prescribed tamoxifen
for a minimum of 5 years, thus chronic activation of GPER by tamoxifen could
provide a subset of primary tumor cells with sufficient Akt signaling (a downstream
target of GPER) to survive the tamoxifen regimen. This idea is supported by
observations of Mo et al., who showed that tamoxifen-resistant tumors were
“re-sensitized” to tamoxifen when co-treated with the GPER-selective antagonist,
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G15 [90, 160]. Together, these observations point to a potential benefit of truly
selective ERα antagonist that do not activate GPER. To date, all of the tested ERα
antagonists,

including

fulvestrant,

raloxifene

and

even

the

presumed

ERα-selective agonist, PPT, have been shown to act as agonists of GPER [23].
Therefore, this makes AB-82P the first molecule of its class to show no activity
towards GPER, making it the first, truly ER-selective antagonist. We acknowledge
that we did not directly test AB-82P binding to GPER, but since AB-82P was
derived from the truly ER-selective agonist, AB-1, it is likely that AB-82P
maintained its non-selectivity toward GPER. Receptor selectivity was previously
maintained when the selective GPER agonist, G-1 was converted to the
GPER-selective antagonists G15 and G36 by modifying the agonist [90, 91].
Therefore, we expect receptor selectivity to be maintained for AB-82P. However,
further testing is required to confirm this. It is also worth mentioning that while our
claim that AB-82P is the first, truly ER-selective antagonist, several new SERDs
(e.g. AZD9496), have been developed, but have not yet been tested for their
selectivity towards GPER [145].
The ability to clinically inhibit ERα in the absence of GPER activation
potentially has significant clinical benefits, including decreasing and/or delaying
the development of endocrine resistance. Although AB-82P is currently the only
compound with this ability, its current therapeutic value is limited due to its affinity
for ERα. In our binding assay, using purified ERα-LBD, we measured an IC50 value
of 0.22 μM. More importantly, in functional assays, we measured IC50 and EC50
values ranging between 2-8 μM, consistent with the need to have ~90% receptor
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occupancy to effectively inhibit E2 action. These results also reveal that addition
of an alkyl chain to the carbon-8 position of AB-1 is detrimental to the affinity of the
molecule (cf. IC50 value for ERα of AB-1, 38 nM vs. that of AB-82P, 0.22 μM). The
addition of the alkyl chain could affect how well AB-82P fits into the binding pocket
of ERα, which would account for the loss in affinity. How this reduced affinity of
AB-82P translates to in vivo efficacy is still unknown and merits further testing.
However, AB-82P has the potential of being improved by modifying its molecular
structure. Hamann et al., showed that modifying AB-1 (termed compound 3), by
addition of a gem-dimethyl and fluorine-group, improved the affinity of AB-1 by
>200-fold [206]. One could speculate, that the addition of these groups to AB-82P
could result in a similar improvement in ERα binding affinity (possibly as low as
1-10 nM) and functionality, thereby making it a better therapeutic candidate.
Endocrine resistance is a major clinical problem. The presence of ERα
mutants that are less sensitive to tamoxifen and fulvestrant, in relapse tumors, is
one mechanism by which tumors evade killing by current endocrine therapies [123,
125]. Therefore, new SERMs and SERDs have to be effective at inhibiting (and
degrading, in the case of SERDs) clinically relevant mutant forms of ERα. We have
shown that AB-82P is effective at degrading (≈40% decrease) one of the most
commonly found ERα mutants in relapse tumors (ERα-Y537S). Furthermore, we
have shown that AB-82P can inhibit cell growth of both a tamoxifen-resistant cell
line and an MCF-7 LTED cell line (a model for aromatase inhibitor resistance [232,
233]). Thus, despite AB-82P’s lower affinity for ERα (vs. fulvestrant), it inhibits the
growth of relevant models of endocrine resistance, albeit at a clinically unfavorable
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concentration for a therapeutic candidate drug.
Tamoxifen has proven to be an effective ERα antagonist, albeit at the
expense of cross-activating GPER. While developing a truly selective ERα
antagonist would circumvent the cross-activation of GPER, this undesirability can
also be avoided through a combinatorial drug approach. Therefore instead of
replacing tamoxifen (and its favored efficacy), adding an additional therapy, which
would block its cross-activation of GPER, might also be beneficial in decreasing
the likelihood of patients developing endocrine resistance. A combination therapy
of tamoxifen and one of the well-known GPER-selective antagonists, G15 or G36,
could be a valid option [90, 91]. One downside to this would be that the increased
risk for developing endometrial cancer (due to the tamoxifen treatment) would still
be present. Furthermore, G15 or G36 would have to outcompete tamoxifen for
GPER binding. Therefore, completely blocking tamoxifen binding to GPER might
not be achieved and the resulting pro-survival signaling would not be fully
prevented. Thus, although a combinatorial approach is feasible, treating with a
single, truly ERα-selective antagonist, like AB-82P would eliminate this
undesirable risk. Furthermore, a single agent therapy would eliminate any potential
side-effects related to the second drug therapy. It should be noted that we have
not tested AB-82P for potential agonist activity in the endometrium, but given its
SERD properties (i.e. inducing ERα degradation), it is likely that AB-82P, like
fulvestrant, is a “pure” ERα antagonist [113].
Aside from its potential therapeutic benefits, AB-82P could also serve as a
tool to better study the intricate signaling pathways of estrogen. Our lab previously
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identified the GPER-selective agonist G-1, and the selective antagonists, G15 and
G36. These ligands have provided researchers with the tools to study the role of
GPER in systems (e.g. MCF-7 cells and in vivo murine studies) where the classical
estrogen receptors are also present. Now with the addition of AB-82P (and AB-1),
researchers can utilize the complementary approach to study the selective roles
of classical estrogen receptors in systems that co-express GPER.
In this report we have identified the first truly ER-selective antagonist that
was derived from our previously identified, ER-selective transcriptional agonist,
AB-1. With mounting evidence that cross-activation of GPER by tamoxifen and
other clinically-used ERα antagonists contributes to the development of endocrine
resistance, the benefits of a truly ER-selective antagonist could be of great
significance. Although AB-82P has poor pharmacological properties (e.g. low
binding affinity for ERα), it could serves as a lead compound presenting the
structural basis for future ER-selective antagonists that could prolong the lives the
breast cancer patients by leading to a decrease and/or delay in the development
of endocrine resistance.
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3.5 Materials and methods
Reagents. E2 (17β-estradiol), 4-hydroxytamoxifen and MG-132 were purchased
from Sigma-Aldrich and ICI182,780 was purchased from Selleckchem. All stock
compounds were dissolved in DMSO unless specified. G-1 was synthesized as
previously described [234]. AB-82P was synthesized by Jeffrey Arterburn at New
Mexico State University (Supplementary Fig. 3.1, detailed chemical synthesis not
shown).

Cell culture. Cell lines were obtained from the American Type Culture Collection.
MCF-7, Hec50 and HEK293 cells were cultured in the DMEM supplemented with
10% FBS, 2 mM L-glutamine, 100 units/mL penicillin and 100 ug/mL streptomycin.
Tamoxifen resistant MCF-7 (TamR), derived from a tamoxifen-resistant tumor
[235], were a gift from Dr. Donald McDonnell (Duke University) and were
maintained in DMEM/F-12 supplemented with 8% FBS and 100 nM 4-OHT.
Long-term

estrogen-deprived

cells

(MCF-7

LTED),

derived

from

an

estrogen-deprived MCF-7 tumor, were also provided by Dr. Donald McDonnell and
were maintained in phenol red-free DMEM/F-12 supplemented with 8%
charcoal-stripped FBS. For E2 deprivation, cells were grown for the indicated times
(with intermediate changes of medium) in phenol red-free DMEM/F-12 medium
supplemented with 10% (or 8%) charcoal-stripped FBS supplemented with 2 mM
L-glutamine, 100 units/mL penicillin and 100 μg/mL streptomycin. All cell lines were
cultured at 37˚C in a humidified 5% CO2 chamber.
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Ligand-binding assays. Binding assays for ERα-LBD and ERβ-LBD were
performed using the LanthaScreen TR-FRET Competitive Binding Assay
(ThermoFisher Scientific) by the SelectScreen Biochemical Nuclear Receptor
Profiling Service (ThermoFisher Scientific). AB-82P was tested at a 10 μM dose
and subsequent 3-fold dilutions for a final 10-point dilution curve.

ERE transcriptional activity. MCF-7 cells stably expressing an ERE-GFP
reporter construct (a kind gift from Dr. Yuri Yamaguchi [230]) were plated in phenol
red-free DMEM/F-12 supplemented with 5% charcoal-stripped FBS in 6-well plates
(150,000 cells/well). After 5 days (with intermediate medium changes on days 2
and 4), cells were treated with the indicated compounds (dissolved in DMSO, 0.1%
final) in the presence or absence of 100 pM E2 for 24 h. Following stimulation,
cells were washed once with PBS and trypsinized with phenol red-free trypsin.
Trypsin was deactivated by adding an equal volume of ice-cold medium and cells
were spun down for 5 min (2,000 rpm) at 4°C. Cells were resuspended in 400 μL
ice-cold PBS, passed through a 0.22 μm filter and analyzed on a BD LSRFortessa
(BD Biosciences) for GFP expression. DMSO-treated cells were used to acquire
background GFP signal. Per experiment, values were normalized to the maximum
value for E2-stimulated cells. This value was the “Top” value obtained when fitting
the E2 curve in Prism GraphPad and set to 100%.

RNA isolation and quantitative real-time PCR. MCF-7 cells were plated in 6-well
plates in DMEM supplemented with 10% FBS (300,000 cells/well). The next day,
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media was changed to phenol red-free DMEM/F-12 supplemented with 5%
charcoal-stripped FBS. Twenty four hours later, cells were stimulated with the
indicated compounds (dissolved in DMSO, 0.1% final) for 16 h and subsequently
washed twice with ice-cold PBS and RNA was extracted using the RNeasy Mini
Kit (Qiagen) according to the manufacturer’s protocol. RNA (100 ng) was reverse
transcribed using the ImProm-II Reverse Transcription System (Promega) with
random hexamer primers according to the manufacturer’s protocol. qPCR was
performed using the 7500 Fast Real-Time PCR System (Applied Biosystems),
SYBR Green PCR Master Mix (Applied BioSystems, Foster City, CA) and 2 μL of
cDNA. Gene expression levels were calculated using the ΔΔCt method and
normalized to that of 18S. Primer sequences used were as follows: 18S Fw 5’TTTTCGGAACTGAGGCCATG, Rv 5’-TGGCAAATGCTTTCGCTCTG. GREB1,
TFF1 and PGR primer sequences were previously published [236, 237].

ERα degradation. MCF-7 cells were plated in DMEM supplemented with 10%
FBS in 6-wells plates (500,000 cells/well). The next day, the media was changed
to phenol red-free DMEM/F-12 supplemented with 10% charcoal-stripped FBS.
Following 48 h of E2 deprivation (one intermediate medium change), cells were
treated for 24 h with the indicated compounds in E2-deprived medium. At the end
of the treatment, cells were washed twice with ice-cold PBS and lysed in RIPA
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 1% Nadeoxycholate and 0.1% SDS) supplemented with protease/phosphatase cocktail
(ThermoFisher Scientific), passed through a 20G needle (12-15 times) and protein
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concentrations determined using the Pierce™ BCA Protein Assay Kit
(ThermoFisher Scientific). Samples (20 ug) were resolved by SDS-PAGE (4-12%
Bis-Tris gel), transferred to nitrocellulose membranes and subjected to Western
blot analysis. Membranes were probed overnight with a rabbit anti-ERα antibody
(Cell Signaling, 1:1000) or mouse anti-Actin antibody (Millipore, 1:5000) in 4%
BSA-TBST at 4˚C followed by a secondary HRP-linked goat anti-rabbit antibody
(1:5000) or HRP-linked goat anti-mouse antibody (1:2500) for 1 h at RT. Bands
were visualized by chemiluminescence and quantified using ImageJ software
(NIH).
For experiments with the MG-132 inhibitor, cells were pre-treated for 1h with
0.1% DMSO or 10 μM MG-132 prior to stimulation with the indicated compounds
for 6 h (in the presence of DMSO or inhibitor). For experiments with the ERαY537S construct, HEK293 cells were seeded (400,000 cells/well) in 6-well plates
in phenol red-free DMEM/F-12 supplemented with 10% charcoal-stripped FBS.
The following day, cells were transfected with 1.5 μg pcDNA-HA-ER Y537S (a gift
from Sarat Chandarlapaty, Addgene plasmid # 49499) using Lipofectamine 3000
(ThermoFisher Scientific) according to the manufacturer’s protocol in medium
lacking pen/strep. Twenty four hours post-transfection, cells were treated with the
indicated compounds for 48 h. Blotting for HA-tag was performed as described
above using a rabbit anti-HA antibody (Cell Signaling, 1:1000) O/N at 4˚C.

Cell viability assay. MCF-7 (and MCF-7 variants) cells were plated (2,500
cells/well) in 96-well plates phenol red-free DMEM/F-12 supplemented with 10%
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charcoal-stripped FBS (8% charcoal-stripped FBS for TamR and MCF-7 LTED
cells). Three days later, cells were treated with the indicated compounds for 5 days
in the presence or absence of 100 pM E2 (one intermediate change of stimulation
medium on day 3). Following stimulation, cell viability was assessed using the
CellTiter-Glo kit (Promega) according to the manufacturer’s protocol and
luminescence was measured on a Biotek Synergy H1 Hybrid Multi-Mode
Microplate Reader (BioTek) using a 1 s integration time.

Statistical analysis. Data was analyzed by one-sample t-test or one-way analysis
of variance (ANOVA) followed by Bonferroni’s post-hoc test. Non-linear regression
curves were determined using a variable slope fit. Values are expressed as mean
± s.e.m.; n equals the number of assay replicates. Statistical significance was
accepted at a P value <0.05. All analyses were carried out using Prism version 5.0
for Windows, GraphPad Software.
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Chapter 4
Discussion
4.1 Overview and significance
Estrogen plays a role in many physiological processes [5]. Its physiological
role is complicated by the existence of three different estrogen receptors (ERα,
ERβ and GPER). Although each of these receptors have been studied for over a
decade, deciphering the role of the individual receptors in a cell type or tissue
expressing both classical ERs and GPER has been challenging due to overlapping
signaling pathways between the classical ERs and GPER.
Selective ligands (agonists and/or antagonists) to an individual receptor
within a receptor family have generally aided in better understanding the roles of
the individual receptors within that family. Identification of GPER-selective ligands,
e.g. G-1 [89], G15 [90] and G36 [91], which show no activity (or binding) towards
ERα and ERβ (G15 shows a low level of reactivity towards ERα at high (>1 μM)
concentrations), have greatly improved our knowledge on the role of GPER in
estrogen biology. However, selective ligands to the classical ERs, lacking cross
selectivity towards GPER have been elusive. The majority of molecules that bind
the classical ERs have been shown to generally activate (or inactivate) GPER [23].
Similarly, obtaining ligand selectivity between ERα and ERβ has also been
challenging due to the high degree of homology between their ligand-binding
pockets [17]. To date, only a few ERα and ERβ subtype-biased ligands have been
identified. The small molecule PPT [65] shows ~400-fold binding preference
towards ERα over ERβ, while the ligand DPN [66] shows ~70-fold binding
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preference towards ERβ over ERα. Importantly, PPT has been shown to activate
GPER [88].
In Chapter 2 we identified the small molecule, AB-1, as a highly selective
ERα/β agonist that showed no binding or activity towards GPER in cell-based
assays (negligible binding was observed at 10 μM AB-1). This marks the
identification of the first truly ERα-selective ligand that shows no binding to GPER.
Interestingly, AB-1 acts not only as an ER-selective ligand, but also as a
functionally selective agonist of the classical ERs, activating only their
transcriptional activity while inhibiting non-genomic ER signaling. Functional
selectivity of an ER ligand has been previously reported with the identification of
PaPEs (pathways preferential estrogens) [203]. PaPEs are ER ligands with very
low affinities for ERα and ERβ (Ki values >10 μM) that have been shown to induce
rapid ERα signaling, but not ERα-mediated transcriptional signaling. It is
hypothesized that the functional selectivity of PaPEs is due to its low affinity for
ERs. This low affinity (which corresponds to a high dissociation rate) is thought to
be sufficient for the activation of rapid, non-genomic signaling (which occurs on a
timescale of seconds to minutes), but not for the activation of genomic signaling
(which occurs on a timescale of hours). This hypothesis would theoretically not
hold true for AB-1, which has a high affinity for the ERs (ERα IC50= 3 nM and ERβ
IC50= 26 nM), implying a potentially novel (and unknown) mechanism through
which AB-1 is regulating its functionally-selective signaling by ERs. Importantly, it
is currently unknown whether PaPEs bind to GPER.
Identification of AB-1 is a significant contribution to the field of estrogen
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biology due to the novelty of its receptor-binding properties (i.e. highly selective
towards both ERs, but not GPER). Being the first ERα/β ligand of its kind will allow
the field to utilize its selective binding properties to study the role of the classical
ERs in the absence of GPER activation. Selective activation of ERs (particularly
ERα) over GPER could generally only occur with a combinatorial approach
employing GPER-targeting small-interfering RNAs (siRNAs) or G15/G36.
However, even then complete prevention of GPER activation is not ensured. Due
to the absence of its binding to GPER, the use of AB-1 will avoid potential
cross-activation of GPER, making scientific observations more conclusive than
those made using GPER-targeting siRNAs or G15/G36. A drawback to using AB-1
would be its inability to induce rapid, non-genomic ER-mediated signaling.
Therefore, it would be limited in its use and could only be used to study the
transcriptional role of ERs in a given system (in the absence of GPER-induced
transcriptional activity). However, since ER signaling consists mainly of
transcriptional activity, AB-1 will still be useful for a wide range of applications.
As the first truly ER-selective (importantly the ERα aspect) agonist, AB-1
will serve as a beneficial tool to selectively study the physiological roles of the
classical ERs; building upon the current set of truly selective ligands (such as G-1,
G15 and G36) to the three known estrogen receptors. To further expand the
collection of truly estrogen receptor-selective ligands, we sought to identify a small
molecule that harbored the same receptor selectivity as AB-1, but having an
opposite functional profile (i.e. being an ER-selective antagonist). Based on
molecular modeling of AB-1 in the ERα-LBD, we identified AB-82P (in Chapter 3),
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which acts as a truly ER-selective antagonist. Its ability to selectively block
E2-induced transcriptional activity of the classical ERs, while not blocking
E2-induced GPER-mediated rapid signaling makes it a valuable and truly
ER-selective antagonist to study estrogen biology. ER antagonists, such as
tamoxifen and fulvestrant, which inhibit both ERα and ERβ, have been previously
identified.

A

subtype-selective

ERα

antagonist,

termed

MPP

(methyl-piperidino-pyrazole), has also been identified [238]. Although these small
molecules can be used to study the role of classical ERs in estrogen biology, they
lack (in the case of e.g. tamoxifen and fulvestrant) true selectivity towards the
classical ERs, acting generally as GPER agonists [23]. Therefore, conclusions
drawn from experiments using these compounds need to be carefully assessed
since GPER could potentially be activated in the experiment. This potential
ligand-induced cross-activation of GPER is absent in the case of AB-82P, making
it a more useful ER-selective ligand. Whether MPP cross-reacts to GPER is
currently unknown. Thus with the identification of AB-82P, the current set of truly
selective ligands to the estrogen receptors consists of a) the truly GPER-selective
ligands G-1 (agonist), G15 (antagonist), G36 (antagonist), GPER-L1 (agonist) [92]
and GPER-L2 (agonist) [92] and b) the truly ER-selective ligands AB-1 (agonist)
and AB-82P (antagonist).
Aside from its role as an ER-selective tool to study the roles of the classical
ERs in estrogen biology, the identification of AB-82P potentially holds significant
clinical value. Estrogen, through ERα, plays an important role in disease,
particularly in breast cancer [93]. Inhibiting ERα signaling is an effective strategy
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in breast cancer therapy due to the pro-tumorigenic role of the receptor. As such,
tamoxifen has been indispensable in treating ERα-positive breast cancers.
Unfortunately, tamoxifen and other clinical SERMs/SERDs, that act as ER
antagonists, cross-activate GPER [23]. This cross-activation of GPER (in particular
by tamoxifen) has been hypothesized to contribute to clinically-observed endocrine
resistance [124, 159, 160, 163]. Therefore, a truly ERα-selective antagonist,
lacking cross-activation of GPER, could potentially delay or reduce the
development of endocrine resistance of ERα-positive breast cancers. With the
identification of AB-82P, it is currently the only known truly ER-selective antagonist
that lacks cross-reactivity towards GPER, making it a prime candidate molecule
for the potential development of new ERα antagonists with favorable clinical
properties (i.e. lacking GPER activity). Newly developing SERDs, such as
AZD9496 [145] have shown great pre-clinical efficacy in treating models of
ERα-positive breast cancers, with some even showing promising preliminary
results in phase I trials [146]. However, their cross-activity towards GPER has not
been assessed. Therefore, it is unknown if their long-term clinical efficacy would
be hindered by their potential cross-activation of GPER and possibly the resulting
contribution to the development of endocrine therapy-resistant relapse tumors.
The potential benefit of a truly ERα-selective antagonist has, to a certain
extent, been indirectly assessed in clinical trials. Gefitinib, an EGFR tyrosine
kinase inhibitor, has been assessed in a phase II clinical trial in combination with
tamoxifen for the treatment of metastatic ERα-positive breast cancer [239]. EGFR
is activated downstream of GPER and is critical for GPER-mediated activation of
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the MAPK and PI3K pathways [72, 75, 82]. Thus, inhibiting EGFR is, to an extent,
similar yet not identical to inhibiting GPER and its downstream pro-survival
signaling pathways. In the gefitinib/tamoxifen phase II trial, Osborne et al. stratified
patients into two groups: patients that had endocrine therapy-naïve metastatic
tumors or who had relapsed while on/after tamoxifen therapy (group 1) and
patients that had relapsed while on/after an AI therapy (group 2) [239]. Each group
was then split into two treatment arms (gefitinib plus tamoxifen or placebo plus
tamoxifen). For group 1, the PFS of the gefitinib plus tamoxifen arm versus placebo
plus tamoxifen arm was 10.9 and 8.8 months, respectively. Although the difference
in PFS was not statistically significant, the authors deemed the treatment strategy
(gefitinib plus tamoxifen) worthy of further investigation. It should be noted that in
the gefinitib plus tamoxifen arm, tamoxifen-mediated GPER cross-activation (and
its resulting activation of EGFR and subsequent pro-survival signaling pathways)
could still occur due to the presence of tamoxifen. Therefore, the extent of EGFR
inhibition (by gefitinib) in the treatment arm is unknown. Nonetheless, the phase II
data, reported by Osborne and colleagues [239], shows a benefit of inhibiting
EGFR signaling in combination with tamoxifen, which is a scenario that could
potentially be achieved using a single, truly ERα-selective antagonist (such as
AB-82P). Thus, a truly ERα-selective antagonist could potentially achieve similar
or even further improved PFS data than that reported in the gefitinib/tamoxifen
phase II trial [239]. Although AB-82P is currently the only know truly ER-selective
antagonist, its current therapeutic value is limited by its poor affinity for ERα, but
this factor has the potential to be improved (discussed in the next section).
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4.2 Future directions
As an ER-selective tool, AB-1 has great scientific value due to its high
affinity for the classical ERs (ERα IC50= 3-38 nM, ERβ IC50= 24-26 nM), however
its affinity for the receptors could be further improved. With regards to affinity, an
improved version of AB-1 has been previously been reported by Hamann et al.,
who showed that modifying AB-1 (termed compound 3), by addition of a
gem-dimethyl and fluorine-group, improved the affinity of the compound by
>200-fold [206]. However, whether this improved compound 3 retains its selectivity
for the classical ERs over GPER is unknown.
Whether AB-1 has any clinical applications is unknown. In the bone,
activation of ERα, by SERMs such as raloxifene, has been shown to be beneficial
for treatment and prevention of postmenopausal osteoporosis [240]. However,
these SERMs act as ERα antagonists in the breast. AB-1, could be used to in the
treatment of osteoporosis, however a potential risk would be an increased risk of
developing breast cancer due to its agonist properties in the breast. Therefore,
whether AB-1 has any clinical application is still unknown, but it is highly applicable
for research purposes.
As previously discussed, the selective properties of AB-82P are potentially
of great clinical significance, however, in its current form, AB-82P does not harbor
much clinical value due to its poor affinity for ERα. AB-1 was employed as the
structural basis for the development of AB-82P. Therefore, the previously
discussed modifications to AB-1, which have been shown to improve its affinity
[206], could be incorporated into AB-82P, potentially improving its affinity for ERα
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and increasing its clinical value. An important aspect of AB-82P that needs to be
assessed is its in vivo activity. AB-82P should be assessed for its antagonist
properties in the classical uterotrophic assay [9], but more importantly, whether it
can inhibit tumor growth in xenograft models of ERα-positive breast cancers (e.g.
MCF-7 xenograft model). Given its poor affinity for ERα, we hypothesize that
AB-82P, in its current form, harbors poor in vivo efficacy. However, this could
potentially be improved by improving the overall affinity of AB-82P for ERα.
Oral bioavailability is a highly desired property in newly developing SERDs
[147-152]. Therefore AB-82P should also be assessed for its oral bioavailability. If
it lacks this property, it could potentially be molecularly altered to achieve this
desired property. It is important to note that all modified versions of AB-82P will
have to be assessed for their activity towards GPER, since modification of AB-82P
could potentially result in loss of its highly desired selectivity towards the classical
ERs over GPER.

4.3 Conclusions
True ligand selectivity for the classical ERs over GPER has, to date, been an
elusive molecular property. In this dissertation we have identified two small
molecules, AB-1 and AB-82P, which harbor this elusive molecular property.
Importantly, they act as an agonist (AB-1) and antagonist (AB-82P) of the classical
ERs. Due to the hypothesized contribution of GPER to the development of
endocrine resistance to ERα-positive breast cancer therapies, AB-82P has
potentially significant clinical value and merits further investigating either in its
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current form or as the structural basis for future ERα-selective antagonist, which
could potentially reduce or delay the development of clinically observed endocrine
resistance to breast cancer therapies.
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APPENDICES
Appendix A: Chapter 2 supplementary methods
Chemical synthesis.
All compounds were synthesized in an efficient fume-hood. All other
commercially available solvents and reagents were purchased and used without
further purification. Preparative chromatography was performed by medium
pressure column chromatography using AnaLogix SuperFlash pre-packed
columns. 1H NMR spectra were acquired using Varian Oxford 300 MHz, Varian
Unity 400 MHz, and 500 MHz spectrometers and

13C

NMR were acquired using

Varian Oxford 75 MHz, Varian Unity 100 MHz and 125 MHz spectrometers at
ambient temperatures (202 oC). 1H NMR spectra in CDCl3 and acetone-d6 were
referred to TMS. Mass spectra were obtained using an Orbitrap Fusion Mass
Spectrometer (Thermo Fisher, San Jose, CA) acquired with funding from NSF MRI
#1626468.

Diethyl 4-methylcyclohex-3-ene-1,1-dicarboxylate.

A sealed tube containing a diethylmalonate (0.800 g, 5.0 mmol), paraformaldehyde
(0.450 g, 15.0 mmol), 2-methyl-1,3-butadiene (0.408 g, 6.0 mmol) and zinc
chloride (0.09 g, 0.66 mmol, 7.5 mol %) in dry tetrahydrofuran (2.5 mL) was stirred
at 70 C for 24 h. The reaction mixture was concentrated under reduced pressure,
diluted with dichloromethane (45 mL) and washed successively with saturated
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aqueous NaHCO3, and H2O (25 mL each), dried over Na2SO4, evaporated in
vacuo, and purified by silica gel column chromatography eluting with ethyl
acetate/hexanes (1: 99) to obtain the pure product as a colorless oil (0.668 g, 57%).
1H

NMR (300 MHz, CDCl3)  5.37-5.35 (m, 1H), 4.18 (q, J =7.23 Hz, 4H), 2.53-

2.51 (m, 2H), 2.16-2.12 (m, 2H), 2.02-1.94 (m, 2H), 1.63 (bs, 3H), 1.23 (t, J = 7.40
Hz, 6H); FT-IR (Neat), 2960, 1731, 1210, 1151, 503 cm-1).

(4-Methylcyclohex-3-ene-1,1-diyl)dimethanol.

A solution of diethyl 4-methylcyclohex-3-ene-1,1-dicarboxylate (0.68 g, 2.83 mmol)
in dry diethylether (5 mL) was added dropwise to a cooled (0C) suspension of
lithium aluminum hydride (0.240 g, 6.32 mmol) in dry diethylether (1 mL) and
allowed to warm to ambient temperature with magnetic stirring under a nitrogen
atmosphere for 3 h. The reaction mixture was cooled in an ice-bath, and worked
up by successive slow addition of water, 10% sodium hydroxide, and three
additional portions of water (240 L each) to yield tractable aluminum salt
precipitates that were filtered, and the filtrate was concentrated and dried under
vacuum to provide the product (0.327 g, 74 % mp 103-108 C). 1H NMR (300 MHz,
CDCl3)  5.30-5.27 (m, 1H), 3.61 (d, J = 5.47 Hz, 4H), 2.13 (t, J = 5.47Hz, 2H),
1.96-1.91 (m, 2H), 1.81-1.77 (m, 2H), 1.66-1.64 (bs, 3H), 1.60 (t, J = 6.64 Hz, 2H);
FT-IR (Neat) 3300, 1610, 1518, 1269, 1071 cm-1.
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4-(5-(hydroxymethyl)-8-methyl-3-oxabicyclo[3.3.1]non-7-en-2-yl))-phenol
[AB-1].

To a solution of the (4-methylcyclohex-3-ene-1,1-diyl)dimethanol (0.161 g, 1.032
mmol) and 4-hydroxybenzaldehyde (0.15 g, 1.23 mmol) in anhydrous acetonitrile
(4 mL) was added 5 mol% hafnium(IV) trifluoromethanesulfonate monohydrate
(0.040 g, 0.051 mmol). The reaction mixture was stirred at ambient temperature
under a nitrogen atmosphere for 18 h. The reaction mixture was quenched with
sat. NaHCO3 (10 mL), diluted with water (25 mL) and the product was extracted
using CH2Cl2 (3x10 mL), dried over Na2SO4, and evaporated in vacuo. The product
was purified by silica gel column chromatography eluted with EtOAc/hexanes
(45:55) to isolate the product as white solid (0.23 g, 86%; mp 164-168 C) (Rf =
0.3). 1H NMR (500 MHz, acetone-d6)  8.03 (bs, 1H), 7.10 (d, J = 8.85 Hz, 2H),
6.71 (d, J = 8.85 Hz, 2H), 5.45-5.46 (m, 1H), 4.42 (d, J = 1.83Hz, 1H), 3.83 (dd, J
= 10.99, 2.83 Hz, 1H), 3.65 (bs, 1H), 3.53 (d, J = 10.99 Hz, 1H), 3.26 (s, 2H), 2.282.26 (m, 1H), 2.22-2.03 (m, 2H), 1.8 (dd, J = 11.6, 2.75 Hz, 1H), 1.65 (m, 1H,),
1.01 (dd, J = 3.97, 2.14 Hz, 3H) (Supplementary Fig. 2.1a); 13C NMR (125 MHz,
CD3COCD3)  157.03, 134.54, 134.16, 127.43, 124.75, 115.36, 80.51, 78.74,
69.90, 44.05, 35.62, 34.85, 34.68, 30.67, 24.4 (Supplementary Fig. 2.1b); FT-IR
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(Neat) 3300, 2975, 1610, 1092, 1051 cm -1. HRMS (m/z) calcd for C16H21O3,
261.1485 [M+ H+]; found, 261.1484 (data not shown). The UV absorbance peak
areas in the HPLC chromatogram of the AB-1 sample (data not shown) were
integrated and demonstrated compound purity of 98.6%.
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Supplementary Figure 2.1. Spectroscopic data of AB-1. (a) 1H NMR (500 MHz) and (b)
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Supplementary Figure 2.2. Competitive ligand-binding assay of the ligand-binding domain
(LBD) of ERα and ERβ. Data are averaged from 2 independent experiments, each performed in
duplicate.

Supplementary Figure 2.3. Ligand-induced protein degradation of ERα. MCF-7 cells were
cultured with the indicated compounds and ERα levels were determined by Western blot. Blots are
representative of at least 4 independent experiments.
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Appendix C: Chapter 3 supplementary figures

Supplementary Figure 3.1. AB-82P synthesis scheme.
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